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Abstract

The promise of D N A vaccination is limited in part by invasive, untargeted
administration. We refined the strategy by incorporating attenuated bacteria to
deliver plasmids directly to APCs.
Initial studies involved human macrophages, which were infected with aroASalmonella typhimurium transformed with eukaryotic vectors encoding 8galactosidase. Results of staining with x-gal demonstrated effective transfer of

plasmids to the target cells, which expressed the reporter gene themselves. Similar
immunocytochemical staining of macrophages infected with bacteria bearing a
eukaryotic vector encoding HIV-1 env showed expression of the viral gene.
Macrophages were also infected with bacteria harboring vectors encoding SIV

env and HIV-1 tat, then subjected to lysis, RNA extraction and RT-PCR. In this way,
conceptual proof of the system was achieved at the level of transcription. Indeed,

the latter case, we recovered a splice product, which specifically confirms eukaryo
expression.
Further studies involved human DCs, cultivated from PBMCs in vitro. We

first used flow cytometry to show that infection with Salmonella induces maturation
a state ultimately necessary for immunogenicity. Once again, bacteria carrying Bgalactosidase vectors were used initially. DCs were also infected with bacteria
carrying a vector encoding HIV-1 gag, then stained for expression of the viral
protein. Both immunocytochemistry and flow cytometry confirmed Gag expression.

Finally, transduced D C s were co-cultivated with autologous T-cells in studies
aimed at detecting interferon-7 expression as a gauge of antigen presentation.
Bacteria were first transformed with eukaryotic vectors encoding influenza Ml
protein. PBMCs were therefore obtained from donors known to have memory

responses to influenza. Co-cultures yielded significant T-cell responses (by ELISpo
and flow cytometry) to DCs transduced to express Ml. We next obtained PBMCs
from HIV-1-infected donors, setting up co-cultures involving DCs infected with
bacteria carrying HIV-1 gag vector. Again, significant T-cell responses were
detected when DCs were transduced to express the viral protein using Salmonella.
Thus, using attenuated S. typhimurium, we can deliver vectors encoding
foreign antigens directly to human APCs. DCs transduced to express viral proteins

can present antigen to autologous T-cells in vitro. As a vaccine tool, this strateg
represents a potential way to achieve non-invasive, targeted delivery of DNA
vaccines.

C h a p t e r I:

Introduction

THE QUEST FOR A VACCINE AGAINST HIV-1
Despite over two decades of effort against it, the global HIV-1 epidemic
continues to plague humanity (1). In the face of such an unprecedented medical
challenge, the scientific community has made important advances in virology,
immunology and pharmacology. Nonetheless, it has proven extremely difficult both
to contain the spread of infection around the world, and to prevent disease
progression in most infected individuals.

As a retrovirus, HIV-1 presents us with unique obstacles to vaccine design (2,
3). Unlike other viral pathogens, for example, HIV-1 integrates into the host cell
genome and therefore remains hidden from the immune system as latent proviral
DNA. Furthermore, viral particles are camouflaged by their heavily glycosylated
envelopes. Those proteins that are effectively exposed as potential immune targets

are highly variable. Indeed, HIV-1 has a substantial degree of genetic diversity, a

well as antigenic heterogeneity. Additionally, the virus employs mechanisms towards
immune evasion, including the shedding of "decoy" monomeric envelope proteins
and the induction of MHC downregulation. Finally, and perhaps most key for viral

persistence within the host, HIV-1 targets the very cells of the immune system that
would otherwise be its foil: A definitive hallmark of .AIDS pathogenesis is the
destruction of CD4+ T-cells.

Apart from fundamental problems posed by the nature of the virus itself, w e
as scientists also face practical challenges imposed by the limitations in our own
knowledge and technology. An accurate animal model for AIDS and realistic
challenge virus are not available, for example, despite the significant utility of
macaques and SIV/SHIV (4). More importantly, we have not yet defined the human

responses that confer protection from HIV-1 disease: What are the immune correlates
of protection in so-called "long-term non-progressors (LTNPs)" and exposed but
uninfected individuals? After 20 years of careful scrutiny of these rare cases, we
not have an unequivocal answer. (5).

When HIV-1 was first identified, our understanding of immune responses was

in fact relatively poor. Thus, early attempts to design a vaccine against the virus

were, in retrospect, misguided, and certainly informed by empiricism above all else
(6). More recent vaccine candidates represent technologies that have emerged only
since the AIDS epidemic began (2). Despite reason for hope, we remain confronted

by the essential question of whether an effective vaccine will be possible at all (
the case of previous viral pathogens, in contrast to HIV-1, it was always clear to

vaccinologists that people who survived acute infection would go on to be immune to
subsequent threat from the same virus. With very few examples of natural immunity
to HIV-1, we lack absolute indicators to guide us in vaccine development (7).
Furthermore, we must accept that sterilizing immunity against HIV-1 may never be

possible (8). Rather, it is likely that the general goal of prophylactic immunizati

should be to prime i m m u n e responses that will allow the host to contain the pathogen
after initial infection (7).

Approaches to HFV-1 vaccine design, therefore, have been necessarily
creative. Established strategies such as live attenuated viruses, inactivated viruses
and subunit vaccines have proven inadequate or unsafe; thus, newer, innovative
technologies continue to be actively investigated (2, 6-8). These experimental
vaccines include live recombinant vectors (pox viruses, adenoviruses, etc.) and DNA
plasmids. As a prime-boost regimen, in fact, the combination of these two novel
approaches has proven especially hopeful (2, 7).

In and of itself, however, DNA vaccination seems a whimsical and unlikely
strategy (9). Nonetheless, its great simplicity, practicality and potential for versatility
have inspired a persistent effort to develop the technique for clinical use. Despite
some promise of in vivo efficacy, there continues to be much speculation as to precise
mechanism of action. Most studies suggest that injected vaccine plasmids are
received and expressed by non-lymphoid tissue with subsequent antigen transfer to
professional antigen-presenting cells (10-12). Limitations of the approach include
invasive administration, untargeted delivery and only modest levels of in situ protein
expression. Many groups have therefore undertaken to refine the strategy towards
enhancing DNA vaccine-elicited immune responses (13, 14).

SALMONELLA AS A VACCINE T O O L
Despite the predominant tendency for infectious pathogens to be transmitted
mucosally, most vaccines approved for human use in the United States must be
administered invasively (Table 1). Indeed, since the discontinuation of the oral

(Sabin) polio vaccine in 2000 (15), the only oral vaccine approved for use in the U
is live attenuated Salmonella typhi, which works against typhoid fever. Among the
few newer vaccines that have been approved in recent years, there is one other

mucosally-administered preparation: a live attenuated influenza virus for intranasa

use. Salmonella, however, is the only live bacteria used as a vaccine (though Vibri
and Mycobacteria are employed in other parts of the world).

Perhaps, then, it is in part because Salmonella spp. were already in place as

clinical agents that several groups undertook to explore their potential use as too
vaccination against other pathogens. Attenuated Salmonella has, for example, been
engineered to express heterologous antigens from HIV, SIV, influenza, Listeria,
pertussis toxin and cholera toxin (16-25). It is clear, however, that serving as in

protein-expression vectors is not the bacteria's greatest strength in this context.

Rather, it is more important to consider the advantages of exploiting Salmonella as
vaccine-delivery vehicles.

The need for effective new vaccine adjuvants for use in strategies against

HIV-1 is well-established (26), and there is particular interest in the development

TARGET

TYPE

ROUTE

diphtheria/tetanus

subunit

IM

meningococcus

subunit

IM

yellow fever virus

live attenuated

SC

Salmonella typhi (typhoid fever)

live attenuated

PO

rabies virus

inactivated

EV1

hepatitis B virus ( H B V )

subunit

IM

hepatitis A virus ( H A V )

inactivated

IM

diphtheria/tetanus/pertussis

subunit

IM

diphtheria/tetanus/pertussis/HBV/poliovirus

subunit/inactivated

IM

HAV/HBV

subunit/inactivated

IM

measles

live attenuated

SC

Haemophilus influenzae type b
(Hib)/meningococcus/HBV
measles/mumps/rubella

subunit

EVI

live attenuated

SC

rubella

live attenuated

SC

mumps

live attenuated

SC

Hib/meningococcus

subunit

IM

pneumococcus

subunit

IM/SC

HBV

subunit

IM

HAV

inactivated

IM

Varicella

live attenuated

SC

influenza

live attenuated

IN

Hib

subunit

IM

pneumococcus

subunit

IM

influenza

subunit

IM

T a b l e 1 Vaccines currently in use in the United States Source: P D R , 58th
edition (2004) (27) EVAintramuscular, SC=subcutaneous, VO=per os (oral),
ENAntranasal.

mucosal adjuvants (28-30). A n adjuvant m a y enhance the efficacy of a vaccine in
more than one way, including by modifying the micro-environment to render it more
receptive to the immunogen (e.g., by serving as a chemoattractant for relevant cells),
or by facilitating and targeting delivery of the vaccine itself. Salmonella as a vaccine
carrier would therefore be functional as its own adjuvant on both levels.
Lymphotropic, intracellular pathogens, the bacteria naturally home to gut-associated
lymphoid tissue, where their endotoxin and invasive behavior make them a
provocative immune stimulus in situ. In fact, other bacterial antigens (including
cholera toxin and E. coli heat-labile enterotoxin) are widely used experimentally in
animals as mucosal adjuvants, but generally deemed too toxic for human use (30).
Importantly, Salmonella would also effectively overcome the baseline tolerogenic
response of the gut towards antigen received into the lumen (31). Administration,
like that of the existent mucosal vaccine against typhoid fever, would mimic natural
Salmonella transmission through the oral route.

The current project, then, represents an attempt to build on the idea of using
attenuated Salmonella as a vaccine vector by using the bacteria instead as vaccine
vehicles. As an experimental approach, conventional DNA vaccination offers no
possibility for non-invasive administration or guided delivery. Furthermore, the
generation of mucosal immunity is very unlikely with direct intramuscular or
subcutaneous injection of plasmids. If, however, we use Salmonella to carry and
deliver our DNA vaccine vectors, we may circumvent these limitations, and further

enhance immunogenicity with built-in bacterial adjuvanticity. First, however, w e
must confirm the conceptual design of this model and evaluate its efficacy in vitro.

C h a p t e r II:

Materials and Methods

BACTERIA
Growth

The attenuated Salmonella typhimurium aroA- strains 33275 and 14028 were
kindly provided by Stanley Lin (Vion Pharmaceuticals, Inc., New Haven, CT).
Bacteria were cultivated on solid and in liquid LB medium supplemented with

antibiotics (tetracycline, ampicillin or kanamycin) 50-lOOftig per mL, as appropria
Extended storage was in 10% glycerol solution at -70°C.

Transformation

Salmonella were grown to logarithmic phase then rendered electro-competent
by chilling on ice and washing three times with sterile H20. Bacteria were then
concentrated to 5.0 x 1010 - 1.0 x 10u/mL for transformation. Electroporation was

carried out using the Gene Pulser II (Bio-Rad Laboratories, Inc., Hercules, CA) wit
cuvette gap 0.1cm, 1.8kV, 25/xFD, 200Q and a time constant of 4-6msec. Each
reaction involved 50/xL of bacterial solution and 0.5 - 2.0/Ag DNA. Following
electroporation, bacteria were grown for 1 hour in SOC medium before being plated.
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Quantification of bacterial density

Correlation of optical density (OD) and Salmonella concentration was
achieved by serial dilutions and plating on solid medium. It was thereby concluded
that an OD600 of 0.8 is approximately equivalent to 2 x 108 bacteria per mL.

Quantification of plasmid content
Salmonella transformed with plasmids of various sizes were grown to an
OD600 of 0.8. The QIAprep Spin Miniprep Kit (Qiagen, Inc., Valencia, CA) was then

used to extract extra-genomic DNA from bacterial solutions of different volumes. An
OD260 of 1.0 was considered equivalent to 50jU,g/mL, and 1-ug of lOOObp of DNA was
equated with 9.1 x 10" molecules (as per New England Biolabs, Beverly, MA). In
this way, it was determined that each transformed bacterium carries 300-900
plasmids.

Infectious protocols

Salmonella were grown overnight at 37°C, then diluted ~1:20 and grown
another 3-4 hours to desired OD. Cells to be infected were washed and incubated
with antibiotic-free medium (RPMI 1640 supplemented with serum, L-glutamine and
Hepes buffer). (Macrophages were left in their original wells in 6-well plates;
dendritic cells were ultimately seeded at 2 x 106/500/iL into Eppendorf® 1.5mL
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tubes.) Cells were infected with the bacteria at desired multiplicities of infection,

then incubated at 37°C for 1 hour. Post-infection, cells were washed 2-3 times with
gentamicin-containing buffer (PBS or HBSS), then incubated in fresh culture medium
as described below. (Dendritic cells were re-plated in medium containing cytokines
at 106/2mL of 12-well plates.) When tetracycline-sensitive Salmonella (33275) were
used, 10/xg of tetracycline was added to each well.

CELL CULTURE
Human blood samples

The New York Blood Center supplied "Leukopacks" derived from
anonymous donors. Whole blood samples were obtained from consenting adult
volunteers, some of whom are part of a cohort of HIV-infected patients seen at the

Rockefeller University Hospital outpatient clinic under the supervision of Dr. Mart
Markowitz.

Isolation of peripheral blood mononuclear cells (PBMCs)

PBMCs were isolated as a buffy coat from human blood samples (or packed
leukocytes) using Ficoll-Hypaque gradient (Robbins Scientific, Sunnyvale, CA).
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H u m a n macrophage cultivation

PBMCs were washed with HBSS and seeded at ~3 x IO7 cells/well of 6-well
plates in RPMI 1640 supplemented with 1% penicillin-streptomycin, 1% Lglutamine, 1% Hepes buffer and 5% heat-inactivated autologous serum. Medium was
changed every two days. Adherent cells were infected as above on day 8 and assayed
in the same wells.

Human dendritic cell cultivation

PBMCs were subjected to CD 14+ selection using magnetic beads and
columns in accordance with the manufacturer's instructions (Miltenyi Biotec,
Auburn, CA). CD 14+ cells were then seeded at 2 x lOVwell of 6-well plates in RPMI
1640 supplemented with 1% penicillin-streptomycin, 1% L-glutamine, 1% Hepes
buffer, 1% heat-inactivated autologous serum (or 5% type AB human serum (Sigma,
St. Louis, MO)), recombinant granulocyte-macrophage colony stimulating factor
(lOOIU/mL; Leukine, Immunex, Seattle, WA) and recombinant EL-4 (20ng/mL;
R&D Systems, Minneapolis, MN). Additional cytokines were added to the cultures
at the same concentration every 2 days. Immature dendritic cells were infected as
above on day 6-8. Mature dendritic cells were obtained by adding IL-1/3, TNF-a. and
IL-6 (R&D Systems, Minneapolis, MN) at lOng/mL, and prostaglandin E2 (Sigma, St.
Louis, MO) at Ipg/mL.
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Dendritic cell/T-cell co-cultivation

After CD 14+ selection, CD 14- cells were cryopreserved in freezing medium
(Gibco, Grand Island, NY) to be used as a source of autologous bulk T-cells once
dendritic cell cultivation was complete. Cells were then defrosted and seeded into

wells of a 96-well plate at 2 x IOVIOOjuL (in early studies) or into the wells of a
well plate at 1.2 x 106/500/nL (in later studies).

Just after peptide pulsing or influenza infection, or approximately 40 hours

after Salmonella infection, dendritic cells were added to achieve the desired ratio

(1:30 in early studies, with final volume of 200/-IL in wells of 96-well plates; or
1:60/1:30 in later studies, with final volume of lmL in wells of 48-well plates).
Culture medium used in DC/T-cell co-cultures was RPMI 1640 supplemented with
1% penicillin-streptomycin, 1% L-glutamine, 1% Hepes buffer and 5% type AB
human serum (Sigma, St. Louis, MO).

Cultivation of murine dendritic cells from bone marrow

Marrow from the femurs and tibias of mice were harvested by flushing the
epiphyseal and medullary cavities with RPMI 1640 using a 3cc syringe fitted with a
25ga x 5/8" needle (BD, Rutherford, NJ). One volume of 1.66% aqueous NH4C1 was
added, followed by incubation on ice for 5 minutes. Antibodies to CD4 (TIB 207,
clone GK 1.5, ATCC, Rockville, MD), CD8 (TIB 150, clone H02.2, ATCC),
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C D 4 5 R B (B220 isoform; TIB 146, clone R A 3 - 3 A 1/6.1, A T C C ) and M H C H (TIB
229, clone B21-2, ATCC) were added (as hybridoma supernatants, at a 1:20 dilution)
to encourage complement-mediated lysis of differentiated lymphocytes and class II
MHC+ cells. Rabbit complement (Pel-Freez Clinical Division, Rogers, AR) was also

added at a 1:15 dilution, and cells were incubated for 1 hour at 37°C. After washin
cells were plated in 24-well plates at ~1 x lOVwell. Medium used was RPMI 1640
supplemented with L-glutamine, 5% heat-inactivated FCS (Gemini Bioproducts,
Calabasas, CA), 1% Hepes buffer, 20ptg/mL gentamicin, 50juM 2-mercaptoethanol
and 666u/mL of recombinant murine granulocyte-macrophage colony stimulating
factor (Kirin Brewery Co., Maebashi, Gunma, Japan). Medium was changed every
two days.

ASSAYS
j8-galactosidase detection with 5-bromo-4-chloro-3-indolyl galactopyranoside (xgal)
Cells to be stained (macrophages or dendritic cells) were incubated with 1%
formaldehyde and 0.2% glutaraldehyde in PBS for 5 minutes at room temperature,
then washed twice with PBS. Staining for /3-galactosidase expression was achieved
by then incubating with 4mM potassium ferrocyanide, 4mM potassium ferricyanide,
ImM magnesium chloride, and 0.4mg/mL x-gal in PBS for 1 hour at 37°C in a nonC02 incubator. Staining was stopped by replacing the solution with PBS.
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Macrophages were kept in their wells for this procedure. Dendritic cells were
either kept in wells, or affixed to a slide using a "cytospin" technique. This

preparation was achieved using "Cytofunnels" and a Cytospin II centrifuge (Shandon,
Pittsburgh, PA). Briefly, 1.0 x IO4 - 1.0 x IO5 cells in 100-150/xL were spun onto

glass slides at 900rpm for 3 minutes. The slides were air-dried for at least 1 hour
then fixed (stabilized) in 100% acetone for 10 minutes before being air-dried once
again.

Immunocytochemistry

Cells were stained using the Vectastain® ABC-AP Kit (Vector Laboratories,

Burlingame, CA). Briefly, cells (either in wells or on slides) were first incubated
with blocking (goat) serum for 20 minutes, then with primary antibody (1:500

dilution of HIV-infected patient's serum) for 30 minutes. Cells were then washed 510 times with PBS, and incubated for 30 minutes with biotinylated secondary (goat
anti-human) antibody. Finally, cells were incubated with the Vectastain® -ABC-AP
Reagent (avidin-biotinylated enzyme complex) for 30 minutes, then washed and
incubated 20-30 minutes with an alkaline phosphatase substrate (Vector® Red).

Flow cytometry

/3-galactosidase activity in dendritic cells was detected with the
DetectaGene™ Green CMFDG lacZ Gene Expression Kit (Molecular Probes, Eugene
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O R ) . Briefly, cells were hypertonically loaded with fluorescein di-/3-Dgalactopyranoside (FDG), a fluorescent substrate of the enzyme. Additionally,
chloroquine was added (to raise lysosomal pH, thereby inhibiting endogenous 8galactosidase activity), as well as propidium iodide (to identify and exclude dead
cells) and verapamil (to enhance signal by blocking efflux of fluorescent reaction
product).

All antibodies used in interferon-7 assays were obtained from BD-Pharmingen
(San Diego, CA) at dilutions recommended by the supplier. Cells were collected
from DC/T-cell co-cultures, pelleted and re-suspended in lmL of medium in 5mL

polypropylene tubes. In studies using cells derived from HIV-infected patients, the
co-stimulatory antibodies aCD28 and oCD49d were added (0.5/jiL/mL), as well as

relevant peptides or the superantigen staphylococcal enterotoxin B (SEB) (Sigma, St

Louis, MO) as a positive control for the assay. The cells were then incubated for 6
hours in the presence of 10.ug/mL brefeldin A (Sigma, St. Louis, MO) at 37°C with
tubes at a 5° angle. At the conclusion of this incubation, 2-uL EDTA was added to
each tube, followed by a 15 minute incubation at room temperature. Cells were then
lysed by the addition of FACS Lysing Solution (BD-Biosciences, San Diego, CA)
followed by another 15 minute room temperature incubation. Permeabilization was
achieved by re-suspension and washing with 0.1% saponin and 0.1% bovine serum
albumin in PBS. Staining with relevant antibodies was carried out at room
temperature for 45 minutes, before washing with the permeabilization solution and
fixation with 1% paraformaldehyde in PBS. Flow cytometry was performed using a
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F A C S Calibur instrument, and flow cytometric analysis using CELL-Quest software
(Becton Dickinson Immunocytometry Systems, San Jose, CA).

ELISpot

MultiscreenHTS Filter Plates (Millipore, Billerica, MA) were used for both
human and mouse assays. For the human interferon-7 ELISpot, plates were coated
with anti-human-interferon-7 1-D1K capture antibody (Diapharma, Mabtech,
Stockholm, Sweden) at a 1:100 dilution in 0.1M NaHC03 buffer (pH=9.5), 100/uL per
well. For the mouse interferon-7 ELISpot, anti-mouse interferon-7 antibody (R&D
Systems, Inc., Minneapolis, MN) was diluted 1:40 in 0.1M NaHC03 buffer,
100/iL/well. Plates were then washed 4 times with 0.05% Tween 20 in PBS, then
blocked with 10% FCS/RPMI1640 (mouse assay) or 5% human serum/RPMI 1640
(human assay), 100juL/well for 1-2 hours at 37°C. Blocking medium was then
removed, and wells were seeded with cells, 150-200 pL total volume per well (0.5-

1.0 x IO6 cells [e.g., splenocytes]/well for mouse assay; 1.0-2.0 x 105 CD14- T-cel

for human assays, with the addition of dendritic cells for varying ratios). Plates w
then incubated overnight at 37°C to allow for antibody capture. On the following
day, plates were washed 4-5 times with 0.05% Tween 20/PBS, then incubated with
detection antibody. For the human assay, biotinylated antibody (7-B6-1 -biotin;
Diapharma, Mabtech, Stockholm, Sweden) was diluted 1:1000 in PBS, then added
50-uL/well; the mouse antibody (R&D Systems, Inc., Minneapolis, MN) was diluted
1:60 in 1.0% BS A/PBS and added 100^L/well. Human assays were then incubated at

18

37°C for 2 hours; mouse assays were incubated at this stage overnight at 4°C. Both
types of assay were next washed again 4 times with 0.05% Tween 20/PBS, then
developed using a blue color Development Module (R&D Systems, Inc.,
Minneapolis, MN). ELISpots were read using a plate-reader and ImmunoSpot®
Software (Cellular Technologies Ltd., Cleveland, OH).

Peptides

A complete set of consensus subtype B HIV-1 Gag was obtained from the
NIH AIDS Research & Reference Reagent Program as 15-mers overlapping by 11.
Lyophilized protein was solubilized and pooled, to be ultimately used at 2jU.g/mL.

co-cultures involving cells from HIV-infected donors, dendritic cells used for posi

control were first incubated with the Gag peptide pool for 1 hour at 37°C (in plain
RPMI 1640), then seeded into wells already containing autologous CD 14- T-cells.
Additionally, for re-stimulation prior to intracellular cytokine staining and flow
cytometry, Gag pool was added directly to co-culture cells and incubated with
brefeldin A for 6 hours at 37°C as previously described.

Influenza virus

Purified human influenza virus (X:31, A/Aichi/68 [H3N2]) was obtained from
Charles River Laboratories (North Franklin, CT). For interferon-7 ELISpot and
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intracellular cytokine staining assays to detect memory T-cell responses to influenza

matrix protein (Ml), influenza-infected autologous dendritic cells provided both th

positive control (in co-culture) and the source of re-stimulation (for all co-cultu
categories). Cells were thus infected at a multiplicity of infection approximately
equal to 2 in RPMI 1640 at 37°C for 1 hour.

PLASMIDS
pTrc-/S and pSLICK-z

/3-galactosidase vectors were kindly provided by Stanley Lin (Vion
Pharmaceuticals, Inc., New Haven, CT). pTrc-/3 encodes the reporter gene under the

control of a prokaryotic Trp-lac hybrid promoter; pSLICK-z encodes the gene under a
CMV promoter. Both plasmids also code for ampicillin resistance.

pVAXlfRYVgag

pVAXl/HIVgag was kindly provided by Yaoxing Huang (Aaron Diamond
AIDS Research Center, The Rockefeller University, New York). It was constructed
by first "codon optimizing" HIV-1 subtype C gag (32-34), then inserting the gene
into pVAXl (Invitrogen, Carlsbad, CA) along with leader sequences (35, 36). The
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plasmid therefore encodes HIV-1 gag under a C M V promoter; it contains a p M B l
origin, BGH polyadenylation signal and kanamycin resistance gene.

penv-gag

penv-gag was kindly provided by Yaoxing Huang (Aaron Diamond AIDS
Research Center, The Rockefeller University, New York). It was constructed by first
modifying the pVAXl vector (Invitrogen, Carlsbad, CA) as follows. The hEFla.
promoter was PCR amplified from pBudCE4.1 (Invitrogen), then cloned into the
EcoRl/Notl site, such that a dual-promoter vector was created. "Codon-optimized"

HIV-1 subtype C env and gag were then inserted, resulting in a vector encoding both
viral genes under separate promoters. The vector also contains a pMBl origin, BGH
polyadenylation signal and kanamycin resistance gene.

Ml vector

A vector encoding influenza matrix protein (Ml) was kindly provided by
Thomas Moran (Mount Sinai School of Medicine, New York). It was constructed by
inserting a gene encoding Ml (WSN strain source) into pCAGGS.MCS (37-40). The

viral gene is therefore under the control of the chicken /3-actin promoter; the vec
also encodes an ampicillin resistance gene.
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pCDNA3.1/SIVe«v and pCDNAl.l/HIVtafrevenv

Vectors encoding SIV env and HIV-1 tat, rev and env were kindly provided
by Zhiwei Chen (Aaron Diamond AIDS Research Center, The Rockefeller
University, New York). Construction of the vectors involved inserting the env gene
from SIVinac239 into pCDNA3.1 (Invitrogen, Carlsbad, CA). Similarly, the region of
the HIV-1 (subtype C) genome comprising env, as well as both tat exons and both rev
exons was inserted into pCDNAl.l (Invitrogen, Carlsbad, CA). Both vectors contain
a CMV promoter and ampicillin resistance gene.

RT-PCR
SIV env

For R T - P C R amplification of SIV env, R N A was extracted from cells using
the RNeasy® Mini Kit (Qiagen, Valencia, CA). The RNase-Free DNase Set (Qiagen,
Valencia, CA) was incorporated into the protocol, as per manufacturer's instructions.
Reverse transcription was then carried out using Superscript™ RNase H-Reverse
Transcriptase (GibcoBRL Life Technologies, Invitrogen, Carlsbad, CA). Nested
PCR was then performed using the following primers:
EF1 5'-ACATTCATGTGGACAAATTGCAGAGGAGA-3'
EF2 5 '-TACTGCAAAATGAATTGGTTTCTTAATTGG-3'
ER1 5'-GGGAGGGGAAGAGAACACTGGCCTATA-3'
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P C R was done in a Perkin-Elmer 9600 thermocycler (Perkin-Elmer, Foster City, C A )
in 100/xL volumes containing 0.5 to 1.0/tg of DNA, lOmM Tris-HCl (pH=8.5), 50mM
KCI, 1.5mM MgCl2, 0.1% Triton X-100, 200 pM each dATP, dGTP, dCTP and
dTTP, 20pmol of each primer and 2.5U of Taq polymerase. The first round of PCR

consisted of an initial cycle at 95°C for 2 minutes, followed by 30 cycles of 95°C f
20 seconds, 45°C for 1.5 minutes and 72°C for 2 minutes, using primers EF1 and
ER1. The second PCR round, using primers EF2 and ER1, consisted of another 30
cycles of 94°C for 20 seconds, 55°C for 1.5 minutes and 72°C for 8 minutes.

HIV-1 tat

For RT-PCR amplification of spliced HFV-1 tat, RNA was extracted from
cells using the Oligotex Direct RNA Mini Kit (Qiagen, Valencia, CA). Reverse
transcription was then carried out using Superscript™ II reverse transcriptase
(GibcoBRL Life Technologies, Invitrogen, Carlsbad, CA). PCR was then performed
using the following primers:
TE 1 5' - ATGG AGCC AGT AG ATCCT AACCT AGAGCC-3'
TE2 5' -CT AATCGAATGGATCTGTTTTTGTCTTGC-3'
PCR was done in an Eppendorf Mastercycler Gradient (Brinkmann, Westbury, NY)
in 50-nL volumes containing 0.5-1.Ojug of DNA, 5pL PCR Buffer II (Perkin-Elmer,
Foster City, CA), 1.5mM MgCl2, 200/iM each dATP, dGTP, dCTP and dTTP,
20pmol of each primer and 0.5.uL Gold taq polymerase (Applied Biosystems, Foster
City, CA). PCR consisted of an initial cycle at 95°C for 10 minutes, followed by 40
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cycles of 95°C for 15 seconds, 58°C for 30 seconds and 72°C for 30 seconds,
concluding with an incubation of 72°C for 10 minutes.

MICE
B A L B / c and C57BL/6

B..ALB/C and C57BL/6 mice were purchased from The Jackson Laboratory
(Bar Harbor, ME).
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C h a p t e r III:

Human macrophages can be transduced in vitro using attenuated
Salmonella typhimurium

INTRODUCTION
Salmonella enterica serovar Typhimurium (S. typhimurium) is a facultative
intracellular pathogen whose preferred host cell is the macrophage (41). Wild-type
Salmonellae, in fact, persist and thrive within the cells (42), which is precisely what
permits them to eventually cause systemic disease (43). The bacteria adhere to and
actively invade macrophages, thereby triggering a cascade of intracellular events that
are associated with cellular activation (44). Using type HI pili, Salmonellae directly
deliver effector proteins to the macrophage (41), a property apparently not shared by
other species of gram-negative bacteria (44).

A block in the common aromatic biosynthesis pathway yields auxotrophic
Salmonellae that require aromatic metabolites for survival. Two such metabolites,
paraaminobenzoic acid and dihydroxybenzoic acid, are not available in mammalian
tissues; thus, bacteria that are aroA- mutants, for example, cannot grow and are
avirulent to their hosts (45). After only a few rounds of division, such auxotrophs die
intracellularly because of their inability to synthesize the aromatic amino acids they
need to replicate (46). Because they are attenuated and non-pathogenic, aromaticdependent Salmonellae have been judged worthy of consideration as anti-bacterial
vaccine candidates (45, 47).
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RESULTS
Attenuated Salmonella can deliver a reporter gene vector to human
macrophages: eukaryotic expression of /3-galactosidase detected by incubation
with a substrate

We were interested in developing Salmonella as an instrument with which to
improve genetic immunization. We hypothesized that we could design a system
wherein attenuated bacteria are used as plasmid-delivery vehicles. Rather than
exploit the protein expression machinery of the bacteria themselves, we would
harness auxotrophic Salmonellae to carry and deliver DNA vaccines to appropriate
target cells (Figure 1).

We began, therefore, by using electroporation to transform aroA- Salmonella
(strain 33275) with each of two vectors, "pTrc-/3" and "pSLICK-z." Both encode the
/3-galactosidase gene, but the former has a prokaryotic (Trp-lac hybrid) promoter,
while the latter uses a CMV promoter (See Chapter II). Observation of the
transformed bacteria in different media confirmed promotional specificity in the
context of these vector backbones: Salmonellae carrying pTrc-/3 can express 8galactosidase; the same strain of Salmonella carrying pSLICK-z cannot. AroASalmonellae were also transformed with other, unrelated vectors (e.g., pEGFP) or left
untransformed altogether.

Primary human macrophages were cultivated in vitro from peripheral blood
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Figure 1 H o w the system would work W e envisioned using attenuated S.
typhimurium to deliver D N A vaccines directly to antigen-presenting cells (APCs).
Bacteria invade the cell or are actively phagocytosed (1). The auxotrophic mutant
Salmonellae would then lyse within the phagosome (2), or escape from the vesicle
into the cytoplasm (4), before disintegrating (5). Either way, the plasmids would be
liberated and imported into the A P C nucleus (3). With subsequent host cell
expression, the foreign proteins can be processed and presented in the context of
M H C class I (andpossibly also M H C class II) molecules (6).
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mononuclear cells ( P B M C s ) , and infected with bacteria. In order to gauge optimal
timing of infection, cell cultures were surveyed and manipulated at different timepoints (day 6-day 8 post-isolation of PBMCs). It was thereby determined that
macrophages (as adherent cells) are most numerous on day 8. Moreover, using
Salmonella bearing prokaryotic vectors encoding GFP, as many as seven bacteria at
once could be fluoroscopically visualized within a single cell following infection at a
multiplicity of 100 (not shown).

Using the basic protocol described (see Chapter II), macrophages were
infected with the various Salmonellae, then co-incubated with x-gal, the 8galactosidase substrate, at different time-points. Based on the degree of staining that
resulted, it was determined that a delay of 36-48 hours post-infection yields the most
extensive reporter gene expression.

Ultimately, we arrived at an effective, precise protocol with which to evaluate
our first hypothesis (Figure 2). To further refine infectious conditions, we varied
multiplicity of infection (MOI), and found manifest evidence of an infectious dosedependency: More /3-galactosidase activity is seen in cultures infected at higher MOI,
with (MOI=100)>(MOI=50)>(MOI=25)>(MOI=1). At the highest MOI tested (100),
the degree of x-gal staining suggested -50% of macrophage expression of the reporter

gene.

Overall staining patterns are described in Table 2. Negative controls included
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Figure 2 The original infectious protocol AroA- Salmonella was transformed
using electroporation with one of two plasmids encoding 8-galactosidase as shown.
Control bacteria were either left untransformed or transformed with irrelevant
("pX") plasmids. Macrophages were cultivated from human peripheral blood
mononuclear cells (PBMCs) using the adhesion method, then infected at M O I shown
on day 8 post-isolation. Following infection, cells were washed with gentamicincontaining medium. Because at this time we were using a tetracycline-sensitive
strain (33275), we also added this antibiotic to ensure intracellular bacterial death.
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Protocol

pTrc-P
(prokaryotic promoter)

pSLICK-z
(eukaryotic promoter)

4

infection of
macrophages

M O I ~ 100

PBMC culture
day 8

GENTAMICIN

TETRACYCLINE

Controls

r

^

£

^
^

uninfected
macrophages

Figure

2

infection with
untransformed
bacteria

infection with
bacteria harboring
irrelevant
plasmids

uninfected macrophages, cells infected with untransformed bacteria and cells infected
with bacteria harboring irrelevant plasmids. In the presence of x-gal, these cultures
showed no blue staining at all (Figure 3A).

Macrophages infected with bacteria bearing the pTrc-/3 vector, on the other
hand, did show some, albeit minimal, staining in the presence of the reporter gene

MACROPHAGES

/3-GALACTOSIDASE

STAINING

I N F E C T E D A T MOl=100

EXPRESSION (BLUE

MORPHOLOGY

B Y ...

COLOR)

nothing

no

n/a

untransformed bacteria

no

n/a

bacteria transformed with

no

n/a

<1%

scattered,

irrelevant plasmids (e.g.,
pUC19,pEGFP)
bacteria transformed with
pTrc-/3 (prokaryotic

punctuate

promoter)
bacteria transformed with

40-50%

diffuse,
intracellular

p S L I C K - z ( C M V promoter)

Table 2

substrate. The intracellular morphology, however, was distinctive: These cells bore a
scattered, punctate pattern, suggestive of vacuolized, contained bacteria that are
actively expressing the /3-galactosidase vector themselves (Figures 4 A and 4B).
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In contrast, cells infected with Salmonellae carrying the p S L I C K - z vector
stained in a diffusely intracellular way, suggesting that the macrophages are
expressing the reporter gene themselves (Figures 3B, 5A and 5B).

In light of these staining patterns, we concluded that it was indeed possible to
employ attenuated S. typhimurium as a plasmid-delivery vehicle. The results of this
initial reporter gene study support the proposition that extra-genomic DNA can be
transferred from an invasive bacterium to its target cell, which goes on to express the
foreign vector itself.
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Figures 3-5 Salmonella can be used to transduce h u m a n macrophages in vitro
such that they express a reporter gene Macrophages were infected with aroASalmonella (33275) at MOI—100. Figure 3A shows cells infected with bacteria
carrying irrelevant plasmids, which yielded no visible blue staining. Figure 3B, on
the other hand, represents cells infected with pSLICK-z, which encodes 8galactosidase under the control of a eukaryotic promoter. Note multiple diffusely
blue macrophages. Figures 4A and 4B show cells infected with Salmonellae bearing
pTrc-8, which contains 8-galactosidase under a prokaryotic promoter. Minimal,
punctuate blue staining is evident, probably reflecting phagocytosed bacteria.
Figures 5A and 5B are two more images of cells infected with Salmonellae carrying
pSLICK-z.
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Attenuated Salmonella can deliver a viral gene vector to h u m a n macrophages:
eukaryotic expression of SIV env detected by RT-PCR

With the vision of a vaccine delivery system in mind, we next chose to
evaluate the system using a viral gene instead of a reporter gene. Furthermore, we
undertook to confirm conceptual design at the level of transcription, instead of
translation.

Therefore, once again we carefully chose our experimental vectors, including
one encoding the env gene of SFVmac239 (pCDNA3.1/SIVe«v). Primers were designed
towards recovery of the env gene transcript (See Chapter II for details). Again, we
transformed aroA- bacteria (33275) and cultivated primary human macrophages from
PBMCs.

After a sufficient period of time post-infection (36-48 hours, as determined

earlier), macrophages were scraped to liberate them from the culture dish, then poo
and lysed. RNA was extracted from the cell lysates in a process involving the
addition of DNase. Finally, RT-PCR was carried out to recover any viral gene
transcripts (Figure 6).
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Figure 6 The infectious protocol used towards R T - P C R Salmonella was
transformed with a eukaryotic vector encoding SIVenv as shown. Macrophages were
infected on day 8 following isolation of human P B M C s . Controls for this experiment
included uninfected macrophages, macrophages infected with bacteria carrying
irrelevant plasmids, and macrophages to which nakedpCDNA3.1/SIVenv was added.
Approximately 40 hours post-infection and washing, the cells were harvested, pooled
and lysed. R N A extraction included a DNase step. RT-PCR employed primers
specific for SIVenv.
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Protocol
pCDNA3.1/SIVem>

infection of
macrophages

M O I ~ 100
• GENTAMICIN

TETRACYCLINE
R N A extraction,
including DNase step

RT-PCR

40h post infection

primers specific for SIVenv

Controls
^•'""''p(
A A!

pCDNA3.1/SIVe«v

R N A extraction,
including DNase step
#
RT-PCR
Figure

6

Overall results of P C R are listed in Table 3. Controls once again included

R T - P C R product
(env transcript)?
reagent control

no

uninfected m a c r o p h a g e s

no

m a c r o p h a g e s infected with bacteria transformed
b y irrelevant plasmids (e.g., p S L I C K - z )

no

m a c r o p h a g e s infected with bacteria harboring
pCDNA3.1/SIVe«v

yes

pure p C D N A 3 . 1 / S I V e n v post-DNase treatment
used in extracting R N A from macrophages

no

Table 3

uninfected macrophages, macrophages infected with untransformed bacteria and
macrophages infected with bacteria carrying irrelevant plasmids (including 8galactosidase vectors). Additionally, sham "pellets" comprising pure D N A were used
as a control for the DNase treatment. P C R with the env primers yielded a product of
the appropriate size (1500bp) only from the cells infected with Salmonellae harboring
p C D N A 3 . 1 /SIVenv (Figure 7).
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Thus, w e believe that w e confirmed the efficacy of our plasmid-delivery
system at the level of transcription. Recovery of the m R N A transcript of SIVenv
from infected macrophages suggests that the attenuated bacteria were able to deliver
the plasmid to their target cells in such a way as to permit the latter to express the
viral gene.

Figure 7 Salmonella can be used to transduce macrophages in vitro such that
they express a viral gene RT-PCR using primers specific for SIVenv performed on
R N A extracted from cell lysates yielded the following results: (A) macrophages
infected with bacteria carryingpCDNA3.1/SIVenv, (B) macrophages infected with
bacteria carrying pSLICK, (C) macrophages infected with bacteria carrying pSLICKz, (D) macrophages infected with untransformed bacteria, (E) uninfected
macrophages, (F) reagent control, and (G) lOObp ladder. Note that only in lane (A)
do we see a band corresponding to the size of SIV env. Not shown are results of the
same RT-PCR done on sham D N A "pellets " comprising 0.01 ng, 0.1 \ig and l.Oyg of
p C D N A3.1/SIVenv, which yielded no bands.
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Attenuated Salmonella can deliver a viral gene vector to h u m a n macrophages:
eukaryotic expression of HIV-1 env detected by immunocytochemistry

We continued studying our system of targeted plasmid delivery using viral

vectors. In an attempt to once again prove efficacy at the level of translation, we
undertook to detect expression of a viral protein using immunocytochemistry. We
therefore transformed aroA- Salmonella with a eukaryotic promoter-driven
expression vector that encodes the HIV-1 genes tat, rev and env
(pCDNAl.l/HIVtof/'evenv). At this time, however, we used a different auxotrophic
Salmonella strain (14028), which is reportedly more invasive than 33275. Human
macrophages were cultivated in the usual manner, then infected in a protocol based
on our previous experience (Figure 8). Macrophages were fixed and blocked before

staining using a Vectastain® alkaline phosphatase (AP)-based kit (See Chapter II fo
details).

Overall results of the staining are listed in Table 4. Initially, a horseradish

M A C R O P H A G E S I N F E C T E D A T MOI=100

Env S T A I N I N G ?

BY...
nothing

no

untransformed bacteria

no

bacteria transformed with

yes ( 5 0 - 8 0 % )

p C D N A l . 1/HIVfatrevenv
Table 4
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Figure 8 The protocol used to infect h u m a n macrophages toward
immunocytochemistry H u m a n macrophages were infected in vitro as usual, as
shown. Approximately 40 hours post-infection and washing, macrophages were fixed
and blocked in their wells. Serum from an individual infected with HIV-1 subtype C
was used for primary antibody in order to be specific for the viral source of the gene
encoded by the vector carried by the bacteria. Secondary antibody conjugated to
alkaline phosphatase (AP) was added, then the cells were incubated with an A P
substrate for development.
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p C D N A l .l/YlIVtatrevenv

pX

^
#
M O I ~ 100
GENTAMICIN

TETRACYCLINE
^V

fixation,
blocking

^

1° A b (infected patient's serum)

2° Ab/alkaline phosphatase (AP)

A P substrate

Figure

8

40h post infection

peroxidase (HRP)-based system was used, but endogenous peroxidase activity within
the macrophages proved difficult to fully neutralize, yielding muddy-appearing
negative control cultures (not shown). Using AP instead, however, permitted very

"clean" staining, with no visible background in the control cultures (Figures 9-11).
Macrophages infected with Salmonellae bearing pCDNALl/HIVta^evenv

demonstrated widespread staining, a pattern consistent with the more invasive strai

(14028) and the high MOI (100) used in this experiment (Figures 9-11). Also visible

among the red-colored macrophages were two persistently colorless types of cells: T
cells (which appeared as smaller, more rounded non-adherent cells) and residual
bacteria (which account for much of the apparent debris in the surrounding medium).

These populations, therefore, functioned as an additional, internal control for the
study.

Attenuated Salmonella can deliver a viral gene vector to h u m a n macrophages:
eukaryotic expression of the HIV tat splice product detected by RT-PCR

Our next challenge was to confirm, unequivocally, that what we had detected
thus far was evidence of eukaryotic, not prokaryotic, expression. Could the
immunocytochemical staining, for example, simply reflect bacterially-expressed
protein that had permeated the macrophage cytosol? Were the bacteria themselves

actually capable of driving a CMV promoter through the use of a cryptic prokaryotic
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Figures 9-11 Salmonella can be used to transduce h u m a n macrophages in vitro
such that they express a viral gene Macrophages were infected with aroASalmonella (14028) at MOI=100. The images represent cells infected with either
untransformed bacteria (Figures 9A, 10A and 11 A ) or Salmonella carrying
p C D N A l . 1VHIVtatrevenv, which encodes the viral genes under the control of a C M V
promoter (Figures 9B, 10B and IIB). Immunocytochemical staining for H I V Env
reveals widespread color, suggesting effective receipt and expression of
pCDNAl.l/HIVtatrevenv by the infected macrophages.
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enhancer, for example (48-53)? Although the /3-galactosidase vectors w e used in our

original study, pTrc-/3 and pSLICK-z, appeared specific for prokaryotic or eukaryot
usage, respectively, we ultimately discovered that a CMV promoter can in fact be
used by Salmonella in the context of certain plasmid backbones (e.g., many

Invitrogen® vectors). A culture of Salmonella transformed to carry a vector (pVAXl)
encoding HIV-1 gag, for example, tests positively for p24 content by ELISA (data
not shown).

We sought, then, to prove the conceptual premise of our system by detecting
evidence of RNA splicing, a uniquely eukaryotic phenomenon (54, 55). Initially, we
took advantage of a HeLa cell-derived multinuclear-activation-of-a-galactosidaseindicator (MAGI) assay (56), which allows us to gauge the presence of HIV-1 Tat by
measuring /3-galactosidase activity as a surrogate marker. Though the assay worked

to our satisfaction (not shown), we later learned that the gene product of the first
exon alone is sufficient to function as a trans activator (57).

We then instead turned to PCR once again. Primers were carefully designed
to flank HIV tat (Figure 12). After infecting human macrophage cultures as before
(e.g., Figure 8) with Salmonella bearing pCDNAl.l/HIWafr-evenv, the cells were

liberated, pooled and lysed (See Figure 6). RT-PCR was carried out after extraction
of mRNA (as explained in Chapter II). Controls included macrophages to which pure
pCDNALl/HIVta-'revenv was added. Results are listed in Table 5 and illustrated
graphically in Figure 13.
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i-H

3
WD

S P L I C E P R O D U C T (tat)
D E T E C T E D B Y RT-PCR?
reagent control

no

uninfected m a c r o p h a g e s / P B M C s

no

macrophages + pCDNAl.l/HIVfatfrevenv

no

macrophages infected with bacteria
harboring p C D N A l . \ / H Y V t a t r e v e n v

yes

Table 5
Our P C R products were limited to the gel lane corresponding to the lysate of
macrophages infected with Salmonella carrying p C D N A l . l/HFV7a//-eve«v. W e
therefore believe that the brightest band represents spliced tat, which can only be a
consequence of macrophage expression. Thus, w e again have confirmation of the
intended design, wherein attenuated Salmonellae serve as vehicles for delivery of
eukaryotic vectors to their macrophage targets.

DISCUSSION
Using bacteria as D N A delivery vehicles for genetic immunization was first
attempted by Jerald Sadoff s team (58, 59). Attenuated Shigella was employed to
deliver a reporter gene vector in vitro to cultured B H K cells, and also generated in
vivo lymphoproliferative responses specific for the same foreign antigen when
administered intranasally to mice. Another group soon followed suit (46), exploring
the possibility of using Salmonella as an orally-administered inoculation bearing
vectors encoding two virulence factors of Listeria. Again, both direct evidence of
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Figure 13 Salmonella can be used to transduce h u m a n macrophages in vitro
such that they express a viral gene RT-PCR using primers designed to recover
spliced HIV-1 tat performed on R N A extracts from cell lysates yielded the following
results: (A) W O b p ladder, (B) reagent control, (C) macrophages infected with
Salmonella bearingpCDNAl. 1 /HIVtatrevenv, (D) uninfected cells, and (E)
macrophages with pure p C D N A l . 1/HIVtatrevenv added. Note that the brightest band
in lane (C) corresponds to a size equivalent to that of full tat (both exons together).
Recovery of a splice product confirms eukaryotic (and not prokaryotic) expression.

genetic transfer to host cells (peritoneal macrophages) as well as systemic immune
responses were documented.

Thus, when we began our investigation, there was a small but sufficiently
promising precedent. As w e undertook our o w n studies, several other groups
continued to pursue the burgeoning model of bacteria as plasmid-delivery vehicles in
vaccine design (60-68). All relevant studies published to date, however, have
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involved either cell lines or murine cells (in vitro or in vivo); our experimentation is
unique in demonstrating the efficacy of the system in primary human cells.

Designing such a system notwithstanding, we are confronted with the question
of its potential utility as a successful vaccine strategy. Are macrophages, for
example, truly the most desirable target cell for our purposes?

Before the primacy of dendritic cells (DCs) was recognized, macrophages
were understood to be important as antigen-presenting cells (APCs) (69). At the very
least, they were known to be capable of expressing MHC class II glycoproteins on
their surface, processing endocytosed antigen and producing IL-1.

While we now appreciate that DCs are the most important APCs (especially
given their role in priming naive T-cells), we nonetheless must accept the
complementary role in presentation played by macrophages. They are, for example,
specialized in the phagocytosis of large particles, including antigens from bacteria
and parasites, whether intracellular or extracellular pathogens. Indeed, their
phagocytotic capacity is a first-line defense, and they are important in mediating
innate immune responses (70).

More important towards our end, however, is their contribution to the effector
phase of adaptive immunity. The ingestion of microorganisms, though a primitive,
non-specific defense, also induces the expression of MHC class II and co-stimulatory
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(e.g., B7) molecules. Furthermore, macrophages also produce cytokines that

stimulate T-cell proliferation and differentiation (e.g., IL-12). In fact, the princ

function of macrophages is ultimately the generation of CD4+ effector T-cells (71)
Activated macrophages also become more efficient APCs, with increased cytokine
production and expression of MHC class JH and co-stimulatory molecules.

Additionally, there is a positive feedback process, by which activated T helper cel
produce interferon (IFN)-7 and CD40L, which, in turn, induce MHC class II and costimulatory molecules (71).

Thus, although macrophages are not necessarily our first choice as vaccine
targets, they are not without relevance or utility in the current context. A more

challenging issue, then, is the well-documented observation that Salmonella invasio
of macrophages induces apoptosis. What if our vaccine kills the very APCs it
targets?

Of the many studies that have characterized and explored Salmonella-induced

cell death, the vast majority (72-82) exclusively involve murine macrophages or cel

lines, while only three related studies (83-85) included human cells to any extent.
Moreover, some have noted directly that S. typhimurium entry into murine

macrophages ". .. causes considerably more eukaryotic cell death than does entry of
the same Salmonella serovar into human macrophage cells" (86). This finding is
consistent with our own work: Despite reports of murine macrophage death
occurring within minutes of Salmonella invasion (72), we routinely surveyed our
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h u m a n cells with trypan blue 36-48 hours post-infection, and found that < 5 % of cells
were dead. One possible explanation for this apparent discrepancy is the difference
across species in host resistance factors. Specifically, in the case of susceptibility to
Salmonella virulence, it has become clear that genes mapping to the Bcg/Ity locus are
important (87-95). There are, however, differences between mice and humans with
respect to the encoded protein that has been identified, natural resistance-associated
membrane protein (NRAMP) (89). Indeed, the Bcg/Ity locus displays considerable
polymorphism, even within a species, yielding corresponding phenotypic variation in
NRAMP. Even functional variability according to the sex of the host has been
observed, suggesting a role for hormonal influences (91). The contribution of loci
other than Bcg/Ity has yet to be fully elucidated (93). Importantly, however, it is
known that the protein product of the mammalian suppressor of svgl (mssl) gene
corresponds to the ATPase part of the 26S protease complex, which is believed to
have a pivotal role in regulating apoptosis. The fact that human macrophages display
a greater degree of mssl expression than murine macrophages (86) is further
consistent with our observations regarding the relative resilience of human cells to
Salmonella invasion.

Another factor to consider in a discussion of the possibility of macrophage
apoptosis is bacterial strain choice. At least one recent study documents the
substantial variability across Salmonella serovars in their cytotoxicity in human
macrophages, including the extent of apoptosis induced (96).
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T h e case for permitting a Salmonella-based vaccine to be invasively delivered
to macrophages is strengthened by one final consideration: the potential for crosspresentation by DCs. While a more detailed discussion of DCs in the context of this
system is forthcoming (See Chapters IV and V), it should be noted here that antigen
from apoptotic cells can be acquired by bystander DCs and cross-presented to T-cells
(97-100). In fact, Mary Jo Wick and colleagues specifically confirmed this process
using murine macrophages rendered apoptotic by Salmonella (78). Thus, it may
ultimately emerge that our method of Salmonella-facilitated genetic immunization is
particularly effective in vivo because of an unintended toxicity to macrophage targets.

52

Chapter IV:
Infection of dendritic cells with Salmonella typhimurium induces

maturation but is also cytotoxic

INTRODUCTION
The importance of mucosal immunogenicity in vaccine design has long been

recognized (101, 102), especially in the case of combating HIV infection and diseas

(103-105). Mucosal surfaces are the primary sites of transmission for most infectio

diseases, and over 75% of all HIV transmission, in particular, occurs by the mucosa
route (105). If we can induce mucosal immunity with vaccination, we may be able to
prevent pathogen entry altogether.

Using S. typhimurium to deliver a vaccine would permit mucosal involvement

at the outset: Inoculation itself would be mucosal, through the oral route into the

digestive tract. Furthermore, the bacteria are known to egress from the gut lumen v
the M cells, which overlie Peyer's patches (106). Once these specialized epithelial
cells are effectively traversed (through transcytosis), Salmonellae reach a large
intraepithelial "pocket" containing T lymphocytes, B lymphocytes and macrophages.
Below the epithelium, the bacteria reach DCs (106-108). Because of this convenient
natural route of administration and targeted entry, live attenuated Salmonella has
previously been proposed as a paradigm of mucosal vaccines (109). In fact, some

have called specifically for vaccines targeting M cells (109-111), and at least one
group has proceeded with an in vivo investigation of such a scheme using reovirus
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vectors (112). Indeed, in order to fully and accurately evaluate the potential for
mucosal as well as systemic immunogenicity, we must perform in vivo studies.

RESULTS
Taking advantage of the OY4/OT mouse model: an attempt to take the system
in vivo

We were interested in exploring the potential strength of our vaccine delivery
system in vivo. Specifically, we hoped to take advantage of so-called "OT I" and

"OT II" mice, which are transgenic for T-cell receptors specific for ovalbumin (OVA

epitopes in the context of MHC class I and II restriction, respectively (113, 114).
felt that the murine model would not only enable us to assess the efficacy of oral
inoculation, but also to examine the extent to which DCs are successfully targeted
the transformed bacteria.

We therefore began by constructing a plasmid vector encoding OVA under

the control of a eukaryotic promoter. After sequencing the vector and confirming it
expressive capacity, we transformed aroA- Salmonella (14028) with it, as before.

Next, we designed three different protocols involving OT mice and the new

OVA vector delivery vehicles. The first of these (Figure 14) was intended simply to

confirm DC maturation and T-cell proliferation following in vitro co-culture. Later
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(Figure 15), w e planned to actually inoculate our animals, and ultimately to look for
more specific T-cell responses (Figure 16).

Thus, we began by cultivating murine bone marrow-derived DCs (BMDCs) in
vitro. Based in part on our protocol for infecting human macrophages (See Chapter
III), we similarly undertook to infect BMDCs with Salmonella using varying MOI
(10-100).

Our plans for further manipulation of the cells were truncated, however, when
we observed severe cytotoxicity, apparently as a direct consequence of exposure to

the bacteria. Staining with trypan blue, for example, revealed almost wholesale dea
of the murine BMDCs (not shown), even at low MOI. Indeed, we are not the first to
observe such toxicity in DCs: Yrlid et al. (115) saw similar rates of Salmonellainduced apoptosis of murine BMDCs, specifically when using the same strain

(14028) that we used to infect the cells. Additionally, others have found Salmonell
exposure to be toxic even to human DCs (116), apparently because of a virulence
factor encoded by the bacterial sipB gene, which activates caspase-1 towards
apoptosis (117). Rescigno and Borrow have therefore proposed, in fact, that such
cytotoxicity may serve teleologically as a mechanism of immune evasion (118).

We found nonetheless that, 24 hours after infection at MOI=10, we were able
to assay some surviving BMDCs for maturation markers, as planned. What cells
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Figures 14-16 A n attempt to take the system in vivo Figures 14-16 illustrate
schematically our original plans to take advantage of the transgenic " O T " mouse
system using ovalbumin (0 VA) as a model antigen.
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remained viable after bacterial infection, therefore, were stained for C D 4 0 , M H C
class II and CD86. Flow cytometry data reveal that the Salmonella-exposed DCs did,

in fact, mature. Moreover, they express relevant surface markers to a greater exten

than DCs incubated with LPS as a positive control (Figure 17). This finding, too, i
consistent with the observations of others (119, 120). Whether LPS-induced
maturation occurs through the use of toll-like receptors (TLRs) (121, 122) or not
(123, 124), it appears that Salmonella-induced NF/cB activation is more pronounced
than that by LPS alone (125).

Designing a vaccination trial to detect mucosal as well as systemic responses:
another attempt to take the system in vivo

Despite our initial frustrations with the murine model, we persisted in hoping
to achieve in vivo success with our DNA vaccine delivery system. Although we had
observed evidence of substantial cytotoxicity on exposure of murine DCs to
Salmonella in vitro, we hypothesized that there would be a greater chance of

efficacious antigen presentation in vivo. Not only would the functional MOI be lowe

with indirect, oral administration, we would also likely benefit from the phenomeno
of bystander DC presentation (78, 97-100). Furthermore, we were inspired by a
number of publications documenting successful immunogenicity with Salmonella

inoculation of mice (46, 60, 63, 65, 66, 126, 127), despite presumed toxicity towar
DCs.
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Figure 1 7 Infection of murine bone marrow-derived dendritic cells ( B M D C s )
with S. typhimurium induces maturation Infection of B M D C s with Salmonella (at
M O I = 1 0 ) is seen to increase expression of relevant surface molecules. L P S was also
added to a pool of uninfected cells as a positive control. Note that bacterial infection
seems to yield a greater degree of maturation than LPS, as reflected in the relative
degrees of expression of the maturation markers (CD-40, MHC-II and CD-86)
detected in this study. "Salm/pVAXl " refers to D C s infected with bacteria harboring
"empty "pVAXl vector; "Salm/pOVA " refers to D C s infected with bacteria carrying
pVAXl-ova. Not shown are the results of staining uninfected, unmanipulated B M D C s
with the same antibodies as a negative control, which demonstrated minimal
expression of the maturation markers studied.
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At a later date, w e therefore proceeded to design and carry out an in vivo trial
involving naive BALB/c mice, which was the species available to us at this time

(Figure 18). The plasmid vector with which we transformed our bacteria in this case
encodes both HIV-1 env and gag under dual eukaryotic promoters. Mice were orally

vaccinated three times over the course of 6 weeks using inocula of varying sizes. T
group of mice serving as positive control was vaccinated with the same DNA vaccine
vector intramuscularly, an approach already known to yield systemic humoral and
cellular responses (128). Finally, both blood and feces were harvested for eventual
ELISA, while splenocytes, mesenteric lymph nodes (MLNs) and Peyer's patches
(PPs) were harvested for ELISpot assays. Once again, however, our efforts were
limited by confounding circumstances: MLN cells proved too contaminated (by

adipose tissue) to assay, and PP cells were too few. Splenocytes, on the other hand
were intact and usable but yielded no evidence of systemic immunity in response to
Env or Gag re-stimulation in vitro. Similarly, humoral responses were seen by
ELISA to be minimal or nil.

We were thus prompted to consider the basis for this apparent vaccination

failure. Was there, for example, still too much APC death with the Salmonella doses

we used? Additionally, we speculated about the possibility of tolerogenesis instead
of immunogenesis: The gut, after all, is evolved for tolerance, and the mucosal
immune system mounts tolerogenic responses most often, as it receives the myriad

antigens associated with microbial flora or proteins in the food stream (31, 101, 1

130). DCs are known to play a role in the mediation of tolerance (131, 132), and ar
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Figures 1 8 a n d 19 A second attempt to take the system in vivo Two brief trials
were designed wherein transformed bacteria were administered orally (PO) to
BALB/c mice. Control groups received the vaccine vectors as naked D N A given
intramuscularly (IM) (Figure 18) or carried by Salmonella given intraperitoneally
(IP) (Figure 19). Doses were given as indicated, and the mice were sacrificed to
permit tissue harvesting. Additionally, blood and feces were harvested during the
course of thefirsttrial (Figure 18).
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also known to be anatomically associated with both M L N s (133) and PPs (134). It

would seem, however, that by virtue of their induction of DC maturation, our vaccin
vehicles could eschew tolerogenesis (135, 136).

We proceeded by attempting a second, shorter in vivo trial involving a lower
dose range and a simpler vector (encoding only HIV-1 gag). Additionally, we

included a new group of mice that were inoculated via the intraperitoneal (IP) rout
(Figure 19). We were also sure to process our MLNs cleanly this time, by using a
lymphocyte-separation medium formulated especially for murine cells.

Results of IFN-y ELISpot assays revealed no spot-forming cells (SFC) from

PPs, and only a moderate response (100 SFC/106 cells) from splenocytes in the group

that had received the highest oral dose (IO9 bacteria). More significantly, the gro
that was vaccinated with the highest IP dose (107 bacteria) yielded -300 SFC/106
from cells of the MLNs.

Thus, we see evidence of the system's efficacy in vivo only perhaps when the
bacteria are delivered directly to APCs - in this case, within the peritoneum.
Peritoneal macrophages, however, are known to be weak APCs (137), although they
do produce a soluble factor that enhances the antigen-presenting capacity of DCs
(138). While some groups have found that murine peritoneal macrophages do have

the ability to prime T-cells (139-141), it may be more likely that DCs derived from
peritoneal precursors did the effective presenting (142-145).
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The weakness or absence of a response with oral administration, however,
merits further consideration. One possible explanation is our Salmonella strain

choice. - Is it so much more toxic than the various other strains used in effective

murine trials (46, 60, 63, 65, 66, 68, 126, 127, 146)? One group, after all, used o
strain (14028) specifically when apoptosis of murine APCs was the desired outcome
(78). Similarly, different Salmonella strains may display distinct physiologic

dynamics with respect to exiting the gut and reaching relevant lymphoid tissue. Thu
the timing of our sample harvesting and immunological assaying may have been suboptimal (147).

Salmonella infection of h u m a n dendritic cells induces maturation

Because of the unique importance of DCs as priming APCs, we wanted to

further confirm the ability of our Salmonella-based vaccine delivery system to reac

and activate these cells. Rather than continue to use murine tissue, however, it wa
sensible instead to return to human cells.

We therefore undertook to isolate human PBMCs and cultivate DCs in vitro

(See Chapter II for protocol details). Infection of the immature cells with Salmone
was carried out in a manner similar to that of our previous protocol involving
macrophages (Figure 20). Although we saw considerably less cytotoxicity on
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exposure to Salmonella than with murine DCs, w e did appreciate a greater level of

cell death relative to human macrophages infected with the same bacteria at the sa
MOI (not shown).

Approximately 36 hours post-infection, the DCs were pooled and stained for

maturation markers. Flow cytometry results of the initial assay are shown in Table

MEAN

VALUES

C D 80

CD83

C D 86

C D 25

UNINFECTED

71.45

45.05

1082.05

17.92

SALMONELLA-INFECTED

101.02

61.84

1655.08

32.28

Table 6

Later, we also stained for DC-LAMP, with LPS added to one pool of cells as a
positive control (Figure 21).
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Figure 2 0 Infection of h u m a n dendritic cells (DCs) with S. typhimurium
induces maturation H u m a n P B M C s were isolated, then subjected to C D 1 4 +
selection. A week-long cultivation of these cells in the presence of G M - C S F and IL-4
yielded immature DCs. Infection with Salmonella was performed at a lower M O I
than macrophages (25), and washing was done carefully, so as not to lose these nonadherent cells.
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W e see, therefore, that Salmonella infection of human D C s results in
increased expression of molecules associated with DC maturity. Furthermore, in the
context of vaccine design, DC maturation is a wholly desirable effect (135). Our

observation that Salmonella induces efficient human DC maturation is consistent wit

the findings of other groups (119, 120, 135, 148). It should also be noted that, as

potential tool of vaccination, Salmonella compares favorably in this regard with ot
microbes, which have apparently evolved instead to interfere with DC maturation
(118).

In addition to the up-regulation of known maturation markers, it has been
observed that Salmonella infection of DCs also generally activates them, resulting

part in the production of chemokines that work to recruit macrophages, neutrophils,

natural killer cells and other DCs (119, 149). At the level of activation of member
the NF/cB family, in fact, Salmonella is seen to activate DCs better than pure LPS
(125). Cytokines secreted by DCs as a consequence of Salnonella exposure include
TNF-a, IL-12, IL-6 and IL-18 (116, 117, 150, 151).
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Figure 21 Infection of h u m a n D C s with S. typhimurium induces maturation
Cells were stained with either an isotype control or antibodies against the maturation
markers listed. Note that C D 8 3 is a surface marker, while D C - L A M P requires that
the cells be permeabilized. Control cells received the additional known maturation
stimulus of pure LPS. Not shown here are similar flow images reflecting enhanced
expression ofCD80, CD83, C D 8 6 and C D 2 5 with Salmonella infection of human
DCs.
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DISCUSSION
While immature DCs are specialized in capturing and processing antigens into
peptides towards MHC presentation, mature DCs are initiators and modulators of the
immune system (131, 152). Indeed, the maturation of DCs is a crucial step in the
generation of an immune response.

The nature of possible interactions between DCs and Salmonella, therefore, is

an important consideration for us. Will the attenuated bacteria be a hindrance or a
help in our attempt to deliver DNA vaccines to APCs? Will Salmonella effectively

target DCs in vivol Will DCs survive their encounter with the bacteria, at least lo
enough to present to, and prime, T-cells? And will our plasmid-delivery vehicles
themselves trigger maturation of DCs, thereby ensuring an APC that is ready for
immunogenesis?

Although macrophages were long regarded as the main target of Salmonella, it
is now known that the bacteria are first internalized by DCs. In fact, one study
suggests that DCs actually represent more receptive host cells than macrophages

(153). Furthermore, in addition to the induction of maturation and general activatio

described herein, bacteria are seen to induce the neo-biosynthesis, stabilization a
surface expression of MHC molecules in DCs (148). Thus, evidence suggests that
Salmonella would likely target and interact with DCs in a manner appropriate for
vaccine delivery.
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It has recently been observed by one group that encounters between
Salmonella and monocytic precursors in the skin prevent differentiation into DCs
(154). Nonetheless, the same investigators have found that encounters between the

bacteria and differentiated DCs yield an effective immune response towards antigens
expressed by the Salmonella (155). Furthermore, LPS and inflammatory cytokines
associated with Salmonella infection are known to stimulate the mobilization of
tissue-based DCs from the periphery to secondary lymphoid organs (156, 157). Thus,
although Salmonella will not encourage the conversion of monocytes to dendritic

cells, it is very likely that they will encounter existent dendritic cells in the c
infection (as with any microbe) or inoculation.

Interestingly, Svensson et al. note that the increased surface expression of
MHC-I, MHC-II, CD86, CD40 and CD54 that they observe on DC encounter with

Salmonella does not require bacterial viability or internalization (120). Thus, it ma

be speculated that bacterially induced maturation and activation on this level is p

a function of LPS exposure, and would therefore likely be a matter of TLR signaling

(121, 122, 124). In this way, bacteria can be considered to harbor and deliver a bui
in vaccine adjuvant (158).

On the other hand, the same group also notes that the up-regulation of CD80

expression does in fact require viable, invasive bacteria and internalization (120).
Thus the mechanism of such up-regulation associated with the maturation process is
unclear. It can be speculated, however, that the bacterially induced release of
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cytokines such as TNF-o; works in a positive feedback manner to encourage
maturation.

If we are to undertake to use Salmonella to deliver vaccines to DCs then, we
must also concern ourselves with the potential effects that bacterial virulence factors
would have on their targets. The possible induction of apoptosis has been established
(vide infra), although we may perhaps avoid this fate by choosing our strain carefully.
But what of mechanisms the bacteria have evolved towards escaping immune
surveillance as they persist within their host cells? Expression of many of the
relevant virulence proteins are under the control of the transcription regulator PhoP.
Studies show, however, that PhoP has no bearing on the ability of DCs to internalize
Salmonella, or to go on to process and present antigens (153). Moreover, PhoP does
not affect the maturation process induced in immature DCs that encounter S.
typhimurium, specifically (120). Thus, it is unlikely that Salmonella virulence factors
would interfere with the use of the bacteria in targeted vaccine delivery.

Hence we see that interaction with Salmonella stimulates DCs to mature, a
critical step towards becoming activators and regulators of T-cells. Such an effect is
precisely what is required of a vaccination tool.
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Chapter V :
Human dendritic cells can be transduced in vitro using attenuated
Salmonella typhimurium

INTRODUCTION
As the most potent and effective APCs known, DCs should be a central
concern in vaccinology. They alone initiate immune responses by stimulating
quiescent, naive and memory T lymphocytes. Indeed, they serve as a unique liaison
between antigen and T-cell; antigens that have no contact with DCs are ignored by
T-cells (159). Furthermore, DCs are the sentinels in immune surveillance and can
migrate when necessary to optimize clonal selection. Moreover, in addition to
activating lymphocytes, they also work to tolerize T-cells to self-anti gens. Thus,
can be a powerful tool for manipulating the immune system (131), and the potential
for targeting DCs should be a major consideration in vaccine design.

Since the singular significance of DCs was recognized, in fact, many groups
have indeed undertaken to target, or otherwise involve, DCs in their immunization
strategies. Against infectious pathogens, in particular, DCs have been specifically
targeted with adenovirus-based vectors (160-162), recombinant yeast vectors (163),

liposome-encapsulated proteins (164), pseudo-typed virus (165) and synthetic peptide
immunogens (166). DCs have also been effectively reached by DNA vaccines (167169), including in the skin through the use of a topical adjuvant (170). Linking
vaccines to Fms-like tyrosine kinase receptor-3 ligand (Flt-3L) (171) or to the
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lysosomal-associated membrane protein 1 ( L A M P 1 ) targeting sequence (172) has
also resulted in successful DC contact.

After designing our system of facilitated DNA vaccine delivery in the context
of human macrophages, we went on to demonstrate that our aroA- bacteria can infect
and mature human DCs. We were therefore inspired to continue working with human

DCs, in order to verify that the strategy itself can be used to target these all-im
cells. We were encouraged, too, by the work of other groups, who had successfully
reached DCs with bacterially-based systems (60, 68, 127, 173-177).

RESULTS
Attenuated Salmonella can deliver a reporter gene vector to human dendritic
cells: eukaryotic expression of/3-galactosidase detected by incubation with
substrates and flow cytometry

. We were interested in reproducing some of our early macrophage studies, this
time in the context of primary human DCs. We therefore once again chose to work
with reporter gene vectors in order to demonstrate manifestly that attenuated
Salmonella can be used to deliver functional plasmids to target cells.

We began then by isolating human PBMCs, then cultivating DCs in vitro, as
before (See Chapter II for procedural details). Using a protocol based on our
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infection of macrophages, w e infected immature D C s with aroA- S. typhimurium
(33275) bearing either pTrc-/3 or pSLICK-z (Figure 22). After 1 hour of exposure to
the bacteria, careful washing with antibiotic-containing medium and overnight

incubation, the /3-galactosidase substrate, x-gal, was added to the wells (See Chapte
II for precise protocol). Overall results of the staining are listed in Table 7.

DENDRITIC CELLS
INFECTED A T MOI=50

/3-GALACTOSIDASE
EXPRESSION

STAINING
MORPHOLOGY

BY...

(BLUE C O L O R )

nothing

no

n/a

untransformed bacteria

no

n/a

bacteria transformed with

no

n/a

<1%

scattered,

irrelevant plasmids (e.g.,
pCDNA3.1/SIVe«v)
bacteria transformed with

punctuate

pTrc-jS (prokaryotic
promoter)
bacteria transformed with

30-50%

diffuse,
intracellular

p S L I C K - z ( C M V promoter)

Table 7
As with macrophages that were infected with these same bacteria, the
difference in staining morphology is clear: Cells infected with Salmonella carrying
the prokaryotic vector show a spottiness suggestive of contained bacteria that are
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Figure 2 2 Salmonella can be used to transduce h u m a n D C s in vitro such that
they express a reporter gene AroA- S. typhimurium (33275) bearing different 8galactosidase vectors, as shown, were used to infect immature human D C s
(M0I=25). Approximately 40 hours post-infection, the cells werefixed,then
incubated with x-gal, a 8-galactosidase substrate.
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22

expressing the reporter gene themselves, while D C s infected with bacteria harboring

the eukaryotic vector stain diffusely, apparently throughout the cytosol (Figures 2

25). At higher magnification, a mature DC phenotype is grossly evident (Figure 25).

As before, when we varied MOI, we appreciated a dose-dependency reflected
in the relative number of cells staining blue per well (not shown). Staining 36-48
hours after infection, for example, we saw very few blue cells per field under low

magnification with MOI=5 (0-4), in contrast to the number of blue cells per field wi
MOI=50 (60-70). We found, however, that human DCs (not unlike murine DCs) are
more sensitive to the cytotoxic effects of the bacteria than human macrophages (as
evident in trypan blue staining after exposure). Thus, optimal MOI for maximal
staining of DCs is 35-50 (as opposed to 85-100 with macrophages).

Using the manifest quantification permitted by this reporter gene model, we
also undertook to compare the ability of our bacteria to deliver pSLICK-z to
immature DCs versus mature DCs. Staining with x-gal revealed that the attenuated

Salmonella targets immature cells more effectively than mature cells (not shown), an

observation that is not surprising given the antigen-capturing, endocytosing functi
of immature DCs in vivo (131).

We next chose to take advantage of the non-adherent nature of DCs, an
experimental convenience that we did not have when working with macrophages.
Thus, we could now manipulate and stain our target cells towards flow cytometric
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Figures 23-25 Salmonella can be used to transduce h u m a n D C s in vitro such
that they express a reporter gene Immature D C s were infected at M O I = 5 0 with
bacteria carrying either pTrc-B or pSLICK-z. Approximately 40 hours post-infection,
cells were incubated with x-gal, a 8-galactosidase substrate. Cells exposed to
bacteria carrying the prokaryotic promoter-driven vector (Figures 23A and 24A)
show spotty, punctuate staining, suggestive of contained bacteria expressing the
vector themselves within the cell D C s infected, on the other hand, with Salmonella
carrying the eukaryotic promoter-driven vector at the same M O I show more
widespread color, with a diffusely intracellular pattern, suggesting D C expression
(Figures 23B and 24B). At higher magnification (Figure 25), a distinctly mature D C
phenotype can be appreciated.
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analysis. O u r initial use of the technology began once m o r e with the /3-galactosidase
reporter gene vectors. Instead of incubating the cells with x-gal, however, we
incubated them with fluorescein di- /3-D-galactopyranoside (FDG), a fluorescent
substrate of the enzyme. Our protocol here also involved incubation with verapamil
(to block efflux of the reaction product), chloroquine (to inhibit endogenous 8galactosidase expression) and propidium iodide (to label dead cells) (See Chapter II
for complete details). Flow cytometry results are shown graphically in Figure 26.

Although we can appreciate the dose-dependency of protein expression seen
with an increase in MOI, we may also note the limitation of cytotoxicity - evident,
for example, in the relative scales of the y-axes in the two graphs. With MOI=50,
there were far fewer viable cells within our analytical gate, which excluded DCs
staining positive for propidium iodide.

Nonetheless, the results of both /3-galactosidase studies involving DCs, like
those of our macrophage experiments, are consistent with an effective Salmonellabased plasmid delivery system. Infected DCs receive and express the vector carried
by the bacteria, even as they are matured and activated. The risk of cytotoxicity can
apparently be minimized by decreasing MOI.
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Figure 2 6 Salmonella can be used to transduce h u m a n D C s in vitro such that
they express a reporter gene Approximately 4 0 hours post-infection, D C s were
incubated with fluoroscein di-8-D-galactopyranoside ( F D G ) , a fluorescent substrate
of 8-galactosidase, as well as verapamil (to minimize efflux of the reaction product)
and chloroquine (to inhibit endogenous 8-galactosidase expression). Additionally,
propidium iodide w a s added to allow us to gate specifically on living cells. Graphs
on the left represent cells infected with bacteria carryingpTrc-8; graphs on the right
reflect D C s infected with pSLICK-z. With the change in M O I , a dose-dependent
effect can be appreciated. Furthermore, the change in y-axis scale suggests an
increase in cytotoxicity with higher M O I .
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Attenuated Salmonella can deliver a viral gene vector to h u m a n D C s :
eukaryotic expression of HIV-1 gag detected by immunocytochemistry and flow
cytometry

We continued to explore our strategy using human DCs because we felt that it

was important to confirm efficacy with this cell population. Once we had evidence o
successful bacterial-assisted transfer of the plasmid encoding /3-galactosidase,
however, we wanted to test the system using a vector containing a viral gene.

Thus, we began this set of experimentation again by transforming aro Abacteria (14028) with a eukaryotic promoter-driven vector, this time a plasmid
encoding HIV-1 gag (pVAXl/HIVgag). This vaccine vector is known to yield
particularly high levels of expression in human cells in part because its genetic
sequence was chosen on the basis of eukaryotic codon preference (See Chapter II
regarding details of plasmid design and construction).

Human PBMCs were isolated in the usual way, and DCs were cultivated as
before. At this time, however, it was determined that the DCs could be more easily
infected and manipulated in small tubes, rather than in wells (Figure 27). In this

fewer cells were lost in washing. Once infected (at MOI=50), the cells were re-plate
for overnight incubation.
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Figure 2 7 The new protocol used to infect h u m a n D C s with Salmonella more
effectively Cells were put into Eppendorf® tubes at 2 x 10 /500\iL, and incubated
with loose caps. Spinning at 2000rpm x 5 minutes permitted more thorough washing,
after which the cells could be re-plated at 10 /2mL culture medium until time of
assay.
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T h efirstw a y in which w e chose to analyze the cells for viral gene expression
was immunocytochemistry. For this purpose, we used a "cytospin" technique to
mount DCs onto glass slides approximately 40 hours post-infection (See Chapter II
for details). Cells were then fixed and blocked before being incubated with HIVinfected patient's serum as a source of primary antibody. (This approach was chosen
to be specific for HIV-1 subtype C, the same clade as the genetic source of the
vector's gag insert.)

Results of the staining are listed in Table 8 and illustrated photographically in
Figures 28-30.

DENDRITIC CELLS INFECTED

AT

Gag

M O I = 5 0 B Y ..

STAINING

bacteria carrying an irrelevant plasmid (e.g.,

- 1 %

pSLICK-z)
bacteria transformed with p V A X l / H I V g a g

-90%

Table 8
Control cells in this study were infected with bacteria carrying an irrelevant plasmid
(e.g., pSLICK-z). Immunocytochemical staining revealed dramatic visible
differences between the two infectious categories, reflecting what we must conclude
is broad, effective uptake and expression of the vaccine vector by the appropriatelyinfected DCs. Indeed, on higher magnification (Figure 30), we can appreciate a
certain deepening of the staining color in the perinuclear huff, suggesting a state of
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active protein production (178), and consistent with the known trafficking and

localization pattern of Gag in human cells (179). The high percentage (90%) of cells

that stained positive for Gag expression is consistent with the relatively optimize

conditions achieved in this study, including invasiveness of bacterial strain (1402
and expressiveness of vector (pVAXl with "codon-optimized" insert).

We proceeded by evaluating the efficacy of bacterial pVAXl /HP/gag
delivery in a second way, taking advantage once again of flow cytometry resources.
In this study, we found that we could successfully employ a commercially-available
antibody that was originally raised against HIV-1 subtype B p24. Despite clade
differences, it seems that there is sufficient homology within gag across subtypes
(180, 181).

Thus, we again infected (MOI=35) human DCs with Salmonella carrying

different vectors, then incubated them with the fluorophore-conjugated antibody (Se
Chapter II for protocol). The cells were ultimately fixed and assayed for protein
expression using flow cytometry. Results are represented graphically in Figure 31.

The flow cytometric measurement of relative levels of p24 (Gag) expression
is consistent with our immunocytochemical results. We see that we can gauge DC
expression of the foreign protein in both a gross histological way and in a more
quantitative fashion.
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Figures 28-30 Salmonella can be used to transduce h u m a n D C s in vitro such
that they express a viral gene D C s were infected at M O I = 5 0 with bacteria carrying
either an irrelevant plasmid (Figures 28A and 29A) or pVAXl/HIVgag (Figures 28B,
29B and 30), which encodes the viral gene under a C M V promoter. Cells were
mounted on glass slides using a "cytospin " approach (in contrast to the cells
illustrated in Figures 23-25). Hence, particulate matter seen represents an artifact of
the technique, which affixes all contents of the medium to the slide at once. (Note that
visible, unstained bacteria may serve as an additional control.) Immunocytochemical
staining was carried out as previously, using patient serum as a source of primary
antibody, and the Vectastain® A B C - A P kit for secondary antibody and substrate.
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DISCUSSION
As a general vaccine strategy, genetic immunization as it was originally
conceived and tested requires augmentation and enhancement for true in vivo
efficacy. With intradermal, subcutaneous or intramuscular administration of naked
DNA, there is no targeted delivery to APCs (except perhaps Langerhans cells in the

skin) (182-184). It has in fact been unclear as to which cells actually receive and

express the genetic material, and which cells present the foreign antigens to T-cel
Indeed, much has been made of the "cross-priming" (185), or "direct" versus
"indirect" priming (186) involved. Whatever the case, there seems to be a general
consensus that steps must be taken towards improvement of the basic approach (182184).

One obvious measure for strengthening the technique would be to ensure that
DCs receive or manufacture the antigen themselves for presentation. A few groups
have therefore already investigated the potential for DC delivery with DNA

vaccination, whether intramuscular (168), subcutaneous (167, 168, 187) or intranasal
(169). Intentional, directed targeting of DNA vaccines to immature DCs with a
concomitant maturation stimulus, however, has not yet been achieved.

As we have already considered (vide infra), immature DCs would have to be
reached and simultaneously matured for a vaccine to induce immunogenicity and

prime naive T-cells (131). It is therefore unlikely that any approach that falls sh

this goal would yield protection from pathogenic challenge. In fact, in addition to
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Figure 31 Salmonella can be used to transduce h u m a n D C s such that they
express a viral gene D C s were infected at MOI=z35 with bacteria carrying either an
"empty" vector (pVAXl) or pVAXl/HIVgag, which uses a eukaryotic promoter to
drive expression of the viral protein. Cells were then incubated with either an isotype
control antibody or a commercially-available antibody against the Gag component,
p24.
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Isotype

D C s infected with Salmonella
carrying "empty" vector

D C s infected with Salmonella
carrying pVAXI/HIVgrag
% max.
count
p24

Figure

31

context of vaccination against infectious disease, D C s are also being actively
investigated as tools of immuno-regulation for treating allograft rejection and
autoimmune disease (188, 189). The need to provide a maturation stimulus for
immunogenicity has also been illustrated in studies involving successful protein
delivery to the DC receptor DEC-205. By conjugating a model antigen (OVA) to an
antibody against DEC-205, Bonifaz et al. did effectively achieve significantly
enhanced levels of DC presentation to T-cells. Without a maturation stimulus (in the
steady-state), however, the effect of the DCs on the T-cells was tolerogenic; only
when oCD40 was added did the delivery of antigen to DCs result in immunogenicity
(190). Indeed, conjugation to oDEC-205 represents one promising strategy towards
direct vaccine targeting to DCs in vivo.

Other approaches to immunization involving DCs have involved attempts to
prime T-cells against tumor antigens. Some of these studies have in fact already
progressed to clinical trials (191, 192), though they generally involve ex vivo
manipulation of the cells before re-infusion.

Thus, a Salmonella-based carrier would certainly allow for some advantages
over other vaccine strategies. We have shown here that the bacteria can not only
deliver DNA vaccines directly to DCs, they also function as a maturation stimulus,
themselves. The system would additionally almost certainly represent "direct"
priming insofar as the APCs would be doing the expressing themselves - although
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"indirect" priming would likely also be at play as a consequence of apoptosis and
macrophage involvement.

In addition to its untargeted administration, conventional DNA vaccination
also requires improvement towards the generation of mucosal immunity (182, 184,
193, 194), especially in challenging HIV-1 infection. Once again we must concern
ourselves with DCs in this regard. Mucosal administration of a vaccine inoculum,
alone, is insufficient to ensure mucosal responses. DCs are found throughout

mucosal tissue, including in intranasal (195), buccal (196), tonsillar (197), tracheal

(198), pulmonary (199), genital (200-202) and intestinal (102, 134, 203-207) regions.

The possibility of tolerogenesis, however, must be avoided, as with any other route

In fact, oral administration in particular warrants caution in this regard, since t
natural function involves tolerogenic responses to antigens.

One group therefore undertook to develop an appropriate adjuvant for use
with an oral inoculum that would target and mature DCs directly. Williamson et al.

found that co-administration of Flt-3L (with or without IL-1) successfully converte
tolerogenic oral inoculation into an immunogenic one (130). The adjuvant, however,
was itself administered through an IP injection.

More relevant to our purposes is a study that investigated the DC migration

patterns within the gut in response to both cholera toxin (as an adjuvant candidate
and S. typhimurium. Both induced migration of DCs from the subepithelial dome
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region of P P m u c o s a into underlying B- and T-cell rich follicles and adjacent
parafollicular T-cell zones (208). Thus, our DNA vaccine delivery vehicles would
likely permit appropriate and effective DC targeting, even within mucosal tissue
following oral administration.
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Chapter V I :
Human dendritic cells, transduced using attenuated Salmonella
typhimurium, can present foreign antigens to autologous T-cells in

vitro

INTRODUCTION
The effort to design a vaccine against HIV-1 has necessitated careful
consideration of precisely which viral antigens are optimal for protective
immunogenicity. Studies involving both CD4+ and CD8+ responses have concluded

that Gag epitopes are important (209-211); therefore, this protein has generally be
incorporated into HIV-1 vaccine designs (212-220).

Assays that have proven useful in evaluating the immunogenic strength of
vaccine candidates include the ELISpot assay, as well as intracellular cytokine
staining (ICS). Both approaches have been used to monitor the role of cytotoxic T
lymphocytes (CTL) in viral infection, and can similarly be employed to quantify
CD8+ T-cell responses to vaccines (221, 222), particularly in terms of IFN-y
expression.

When human subjects are not available to serve as donors of HlV-primed

cells, it is more convenient to test vaccine strategies in the context of another v
infection. Influenza, therefore, represents a practical model system, as there is

widespread exposure to (and vaccination against) this pathogen in the United States
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A s a model antigen, then, influenza matrix protein (Ml) is an appropriate choice for
experimental vaccine design, since it is highly conserved across types and strains
(223-226), and it is the most abundant protein in the viral particle (226, 227).

Furthermore, CTL responses to Ml are seen to confer protection from viral challenge
in mice (228, 229). Indeed, the influenza-Mi model system has been useful in

evaluating DC presentation of antigen to T-cells both in vitro and in vivo (229-233

Although HIV-1 certainly represents a very different sort of pathogen than influenz

and while AIDS pathogenesis is very distinct from the course of influenza infection

is not inappropriate to test HIV-1 vaccine strategies in an influenza-based system.
cells that are primed against Ml are, for example, a practical tool for evaluating
basic potential for antigen presentation by autologous DCs targeted with a DNA
vaccine.

RESULTS
Attenuated Salmonella can deliver a DNA vaccine vector to dendritic cells
towards effective antigen presentation: autologous T-cell responses detected by
ELISpot and flow cytometry

We were interested in evaluating the potential for antigen presentation by
human DCs transduced to express a foreign protein using attenuated S. typhimurium.
We therefore isolated PBMCs from HIV-1 infected donors, then set up co-cultures
involving DCs and T-cells. Gag peptide pools were used to pulse DCs as a positive
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control. Other D C s were infected at M O I = 3 5 with aroA- Salmonella (strain 14028)
bearing a vector encoding HIV-1 gag (pVAXl/HIVgag). T-cell responses were

assessed by staining cells for IFN-y an(l measuring expression using flow cytometry

Our initial studies proved impractical, however, because Gag-specific CD8+

T-cells failed to proliferate over time in vitro, even in co-culture with Gag-pulse

DCs. Indeed, it has been seen by others that CD8+ T-cells specific for viral antig
from most HIV-1 infected donors do not proliferate in co-culture (234), even with
mature DCs present (235).

We therefore turned to an alternative infectious context in which to monitor

antigen presentation. It has previously been seen that most local healthy volunteer
demonstrate CD8+ T-cell responses (by ELISpot and flow cytometry for IFN-y

expression) specific for influenza (236). Thus, we designed a protocol for setting u
DC/T-cell co-cultures towards IFN-y ELISpot and ICS analysis of T-cell responses
(Figure 32). Blood samples from eight donors were ultimately processed as follows.
PBMCs were isolated, then separated into CD 14+ and CD 14- populations (See
Chapter II for details). The latter were kept frozen during the 6- or 7-day period

required to cultivate DCs from the former. Before being seeded into a 96-well plate

for co-culture (at a 1:30 ratio) with defrosted autologous T-cells, DCs were either
infected with influenza as a positive control, infected with Salmonella (14028)
bearing a vaccine vector (at MOI=35), or left unmanipulated as a negative control.
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Figure 3 2 The basic protocol used to set up DC/T-cell co-cultures and detect
effective antigen presentation P B M C s were isolated from whole blood, then
subjected to C D 14+ selection using Miltenyi Biotec® magnetic beads (See Chapter II
for details). C D 14- cells were frozen during the 6-7 days it took to cultivate D C s
from the C D 1 4 + cells using the cytokines indicated. D C s were incubated with virus,
peptides, bacteria or plain cytokines before being seeded into co-culture with
autologous T-cells (in either a 96-well plate or a 48-well plate, at a 1:30 ratio or
1:60 ratio). Peptide and virus incubations were carried out just prior to seeding;
infection with bacteria was carried out approximately 40 hours before seeding into
co-culture. T-cell expression of IFN-y was analyzed at different time-points using the
ELISpot assay or intracellular cytokine staining (ICS) and flow cytometry.
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Vaccine plasmids employed were either "empty" p V A X l (Invitrogen®) or an
expression vector (pCAGGS) encoding influenza Ml protein. Assays for IFN-y
expression were carried out at day 0 and day 10 or 14.

Overall ELISpot results are shown in Figure 33. In general, co-cultures

involving DCs that were infected with Salmonella carrying Ml vector yielded greater
T-cell responses than co-cultures involving influenza-infected DCs. Co-cultures
containing DCs infected with Salmonella bearing "empty" vector usually showed

some T-cell responses at day 0, which diminished over time, revealing a significant
gap between this category and co-cultures with DCs infected by Ml vector-bearing

bacteria. Indeed, the initial IFN-y expression detected in co-cultures involving DC
infected by Salmonella carrying pVAXl could represent a memory response to the
bacterial vehicle itself. In contrast to all three co-culture categories involving
infected DCs, control DCs were seen to stimulate autologous T-cells to a minimal
extent (Figure 33).

A subset of the same donor samples was stained for intracellular IFN-y

expression using a fluorophore-labeled antibody, then analyzed using flow cytometry

As with the ELISpot results, a greater difference between the IFN-y expression from
co-cultures containing DCs infected by pVAXl -bearing Salmonella and co-cultures
containing DCs infected by Ml vector-bearing Salmonella was seen as the co-culture
was carried out for 10-14 days (Figure 34A and B). Additionally, it was confirmed
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Figure 3 3 ELISpot assay results from antigen presentation studies using the
influenza model system DC/T-cell co-cultures were set up at a 1:30 ratio in 96-well
plates with D C s infected as indicated (MOI=35 for Salmonella). Cells were then
assayed at different time-points using ELISpot, with re-stimulation (just prior to
assaying) provided by the addition of autologous influenza-infected DCs, again at a
1:30 ratio. Results shown in (A) summarize data from eight different donors at
sixteen different time-points. (B) represents a single donor, illustrating the general
trends observed. Co-cultures involving D C s infected with Salmonella carrying
"empty" vector, for example, tended to display IFN-y T-cell responses early on,
which would then diminish over time. (N.B: Values are normalizedfor occasional
assay background.)
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F i g u r e 3 4 Intracellular cytokine staining (ICS) results from antigen
presentation studies using the influenza model system DC/T-cell co-cultures were
set up at a 1:30 ratio in 96-well plates with D C s infected as indicated. Cells were
then assayed at different time-points using I C S and flow cytometry, with restimulation provided by the addition of autologous influenza-infected D C s . (A) shows
data from one donor, illustrating the general pattern observed at early time-points
(day 0 in this case), including relatively close levels of IFN-y expression between the
two co-culture categories involving Salmonella-infected D C s . (B) illustrates h o w the
gap between the two categories broadens over time (after 10 days in this case), with
co-cultures involving D C s infected with Salmonella carrying M l vector yielding
consistently higher levels of T-cell IFN-y expression. (C) illustrates the dominance of
C D 8 + responses, even, as shown here, at day 0.
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that most of the IFN-y expression was by C D 8 + T-cells (Figure 34C). Neither the
ELISpot data nor the ICS studies, however, revealed significant Ml-specific T-cell

proliferation over time (i.e., expansion) in response to DCs infected with Salmonel
carrying Ml vectors (Figure 33B, e.g.).

In the course of working with the influenza/Ml model system, we came

across an exceptional case that inspired us to explore innate immune responses in t
context of the co-cultures (Figure 35). This anonymous donor displayed relatively

robust Ml-specific T-cell responses, especially in cultures containing DCs infected
with Salmonella bearing Ml vectors (Figure 35A). In staining for CD4 and CD8,
however, it appeared that the EFN-Y-expressing T-cells were neither CD4+ nor CD8+
(Figure 35B and C). With our subsequent samples, therefore, we undertook to rule
out NK and yd cells by staining for CD3 and yd, respectively (Figure 36).
Responding cells in these cases were thus seen to be CD3+ and y<5-. Nonetheless,
closer scrutiny of CD3 patterns (Figure 37 A) suggested that a more definitive
investigation of the possible role of NK cells be undertaken. Subsequent samples
were therefore stained for CD56 (Figure 37B). IFN-Y-expressing cells were thus

consistently found to be CD56- (and yd-), which confirms that they are not NK cells.
Indeed, Ml-specific IFN-Y-secreting T-cells were never again found to be CD8-

/CD4-; the donor that triggered our exploration of innate immune responses proved to
be anomalous.
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Figure 3 5 A n interesting case of apparent non-CD8+/CD4+ responses to
presentation of M l antigen The graphs illustrate data derived (at day 14) from the
cells of one of eight anonymous donors, which were used to analyze D C presentation
of influenza M l antigen to autologous T-cells. As seen in (A), this sample yielded
relatively high levels of IFN-y expression in the co-culture involving D C s infected
with Salmonella carrying M l vector. Staining for C D 4 (B) and C D 8 (C), however,
suggested that the responses were from CD8-/CD4- cells, which was an unexpected
finding.
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Figure 3 6 Co-cultures stained for C D 3 and y^ The previous case (Figure 35)
inspired an exploration of the possible role of the innate i m m u n e system in mediating
responses to D C presentation of M l antigen, particularly w h e n Salmonella vehicles
are involved. Co-culture cells were therefore stained for C D 3 (to rule out N K cell
activity) and yd (to rule out yd cell activity). A s illustrated, responsive T-cells are
clearly C D 3 - and yd-.
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Figure 3 7 Definitive flow cytometric exclusion of N K involvement in co-culture
responses to D C presentation of M l antigen In comparing C D 3 staining patterns
between the two co-culture categories indicated (A), it appeared that cells exposed to
D C s infected with Salmonella carrying M l vector expressed C D 3 to a lesser extent
than cells from co-cultures containing influenza-infected DCs. In order to definitively
rule out N K cell involvement, therefore, cells were stained for C D 5 6 (B). IFN-ysecreting cells were thus seen to be CD56-, confirming that they are not NKs.
(Indeed, no IL-2 was added to these co-cultures, making it unlikely that any N K cells
would survive extended cultivation.) Similarly, IFN-y-secreting cells were
consistently found to be y5- (C).
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A n y distinction in C D 3 expression between IFN-Y-expressing T-cellsfromcocultures with influenza-infected DCs and T-cells from co-cultures with Salmonellainfected DCs (Figure 3 7A) can perhaps be explained by a qualitative difference in
maturation between the two DC populations: DCs that were pulsed with virus were
first exposed to a cytokine cocktail (IL-6, IL-1 ft TNF-a and prostaglandin E2) in
order to mature them. In contrast, DCs infected with bacteria were stimulated to
mature only by the Salmonellae themselves, presumably through a TLR (121, 122,
124). It is thus possible that the two pools of DCs attained different levels of

maturation or activation, which, in turn, would have influenced the way in which th
interacted with and activated T-cells.

We decided to return to the HIV model system to confirm the ability of DCs
infected by Salmonella vehicles to present vaccine antigens. In order to have an

effective positive control, however, it was necessary this time to obtain blood sam
from HIV-1-infected LTNPs, since it has been established that HIV-1-specific CD8+
T-cells proliferate in vitro only when derived from LTNPs (234, 235). Thus, we can
use the extent of expansion of LTNP T-cells in co-culture with autologous Gag-

pulsed DCs as a standard of comparison (235) to T-cell proliferation in co-culture
with DCs infected by Salmonella carrying DNA vaccine vectors. We therefore
acquired blood samples from three known LTNPs, and proceeded to isolate PBMCs

and set up co-cultures as before. Briefly, cells were subjected to CD 14+ selection

towards DC cultivation, while CD 14- cells were frozen until the time of co-culture
Before the two populations of cells were united, immature DCs were either matured

103

with cytokines then left unmanipulated, matured with cytokines then incubated with
Gag peptide pool, infected (at MOI=35) with Salmonella (14028) carrying pVAXl,
or infected (at MOI=35) with Salmonella (14028) carrying pVAXl/HIVgag. The
addition of maturation cytokines and infection with Salmonella were carried out

approximately 40 hours prior to starting the co-culture; pulsing with Gag was carri

out immediately prior to starting the co-culture. DCs were carefully washed (and re

plated, when appropriate) before being seeded into the wells of 48-well plates with
cells at a ratio of 1:60.

T-cells were sampled for analysis early in the co-culture (day 2-4) and again

later on (day 9-10). At these time-points, cells were stained with fluorophore-label
anti-IFN-Y antibody and assayed by flow cytometry to quantify expression of the

cytokine. Results of the analysis of co-cultures from all three donors are shown in
Figures 38-40. Cells were simultaneously stained for CD69 expression to better

focus on activated T-cells. Early time-points suggest a general state of activation

secretion in response to Gag re-stimulation in vitro from all co-culture categories
including those containing mature but otherwise unmanipulated DCs. Later in the
course of co-culture, however, we see, as expected, expansion of the responsive Tcells in the positive control category, wherein DCs were pulsed with a Gag peptide
pool. The T-cells from co-cultures involving DCs infected with Salmonella bearing
gag vectors do not expand as much over time, though there still appear to be
significant differences between this category and the T-cells from co-cultures

involving DCs infected with bacteria bearing "empty" vector. On visual inspection o
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Figures 38-40 Co-cultures derived from HIV-infected L T N P s Data from three
different L T N P donors are illustrated. Cells were processed as before towards
separation of D C s from T-cells. D C s were either left unmanipulated, pulsed with a
G a g peptide pool, or infected (at M O I = 3 5 ) with Salmonella carrying one of two
vectors, as labeled. Cultures were set up in 48-well plates, with a D C : T ratio of
1:60. Before assaying, all categories of cells were re-stimulated with Gag, plain
medium or SEB, as indicated. Early co-culture time-points reflect general (evidently
non-specific) T-cell activation and IFN-y secretion. Later time-points, however, s h o w
a decrease in T-cell responses from co-cultures involving unmanipulated D C s , a n d
D C s infected with Salmonella carrying "empty" vector. Although specific T-cell
populations from co-cultures involving Gag-pulsed D C s are seen to expand over
time, responding T-cells from co-cultures involving D C s infected with Salmonella
carrying gag vector do not consistently proliferate in vitro. Nonetheless, there is a
consistent gap between the two Salmonella-infected D C co-culture categories at the
later time-points.
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the co-cultures, in fact, it could be appreciated that most of the D C s exposed to
Salmonella were dying, and the corresponding co-cultures generally looked
unhealthy.

We therefore concluded that bacteria-induced cytotoxicity was interfering
with, and ultimately preventing, effective DC presentation and consequent T-cell

proliferation over time. We thus decided to lower MOI with our next pool of DCs for
co-cultivation with autologous T-cells. The DCs of our subsequent blood sample
were therefore infected with Salmonella carrying pVAXl/HIVgag at three different

MOIs: 30, 15 and 5. Results of staining co-culture T-cells for IFN-7 expression are
shown in Figure 41. Though the absolute degree of expansion at day 10 is only
moderate, there is a clear inverse dose-dependency (in contrast to assays for

expression), indicating that increased MOI probably results in a counter-productive
degree of DC cytotoxicity.

We proceeded to obtain four more blood samples from HIV-infected patients
known to yield proliferative T-cell responses in vitro when restimulated with Gagpulsed autologous DCs (237). We decided at this time not only to greatly reduce our
MOI, but also to slightly modify our co-culture protocol, as follows. We performed
day 0 whole blood screenings for T-cell (CD4+ and CD8+) responsiveness to Gag re-

stimulation in vitro in order to establish a baseline potential for IFN-7 secretion

then set up DC/T-cell co-cultures as before, but we now had sufficient cell numbers
for a 1:30 ratio in the wells of 48-well plates. DCs were infected with Salmonella
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Figure 41 The effect of decreasing M O I on subsequent antigen presentation
by D C s in co-culture As before, DC/T-cell co-cultures were set up using cells from
a known HIV-infected blood donor. Co-cultures were again carried out in 48-well
plates with a DC:T-cell ratio of 1:60. D C s infected with Salmonella carrying gag
vector, however, were infected at three different M O I s this time, as indicated. The
data reveal progressively increasing IFN-y T-cell responses as M O I decreases,
suggesting more effective antigen presentation secondary to diminished cytotoxicity.
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M O I = l , 2.5 and 5. Maturation cytokines were added to all D C s , including those
infected with bacteria. Co-culture T-cells were analyzed for IFN-7 expression on day
6. Results of ICS and flow cytometry are shown in Figures 42-45.

The data suggest that an optimal balance was achieved between bacterial
cytotoxicity and effective vaccine delivery towards antigen presentation. Indeed, the
maximal degree of cytokine expression in response to DCs infected with Salmonella
bearing gag vectors generally exceeds that in response to DCs pulsed with Gag
peptide pool as a positive control. Additionally, the absolute peak levels of IFN-7
expression seem to be greater from co-cultures involving DCs infected with
Salmonella carrying pVAXl/HrVgag than from co-cultures involving Gag-pulsed
DCs.

One possibly significant experimental detail to consider here, however, is the
addition of maturation cytokines to all DCs destined for co-culture, including those
infected with Salmonella. This modification, intended to better control experimental
conditions, reflects an approach that is distinct from previous co-cultures. Thus, we
were not in this instance dependent on bacterially induced maturation of DCs for
immunogenic readiness. Indeed, it may be useful in the future to examine the degree
of DC maturation possible with infection at the low MOIs used in these studies.

Although optimal responses appear on average to plateau with co-culture DCs
infected at MOI =2.5, the results also seem to reflect qualitative and quantitative
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Figures 42-45 Dramatic increase in effective antigen presentation with further
reduction of M O I Blood from HIV-1-infected donors was once again processed for
co-culture and ICS. Studies were streamlined to eliminate redundant positive (SEB)
and negative (unmanipulated DCs) controls, in order to increase cell number for
analysis. More definitive controls were provided by D C s pulsed with Gag peptide
pool (positive) and D C s infected with Salmonella bearing "empty " vector (negative).
After manipulation, D C s were seeded into co-culture with autologous T-cells at a
1:30 ratio in 4 8-well plates. Cells from all four co-cultures were stained for IFN-y
expression and analyzed by flow cytometry on day 6. (Gag peptide pool provided the
re-stimulation.) Results from all donors reveal significant degrees of IFN-y
expression from T-cells that were co-cultivated with D C s infected with Salmonella
carrying gag vector. C D 8 + responses are seen to plateau with MOI—2.5.
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differences across individuals. One explanation for this phenomenon m a y simply be
different medical histories of Salmonella exposure among the patients, since it is

known that this may affect subsequent responses to the bacteria as vaccine delivery
vehicles (238). Similarly, there are polymorphisms in the genes that encode host
resistance factors in humans (89, 91, 93) such that individuals are likely to have
distinct immunologic responses (and therefore vulnerabilities) to microbial
pathogens, which would affect their reception to microbial vaccine vehicles.

Finally, it has emerged recently that there is a continuum of memory CD8+ T-

cell subsets involving an eventual conversion of so-called "effector" memory T-cell
to "central" memory T-cells. It is the latter subset that comprises cells that are
capable of persisting and proliferating (239). We believe, therefore, that the
expanding, IFN-7-secreting T-cell populations that we detect in our ICS assays are
central memory T-cells. Thus, because our individual patients were sampled at

different points in their infection and disease course, it is possible that their T
were assayed at different points in the effector to central memory continuum, and,
thus, with different proportions of proliferative subsets present.

DISCUSSION
We chose to measure T-cell IFN-7 expression as a gauge of the potential for
DCs infected with Salmonella carrying DNA vaccine vectors to present antigen.

Accepting IFN-Yas an appropriate cytokine marker of memory T-cell activation (and,
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therefore, of effective D C antigen presentation) presumes that it is an accurate
indicator of functional (central) memory T-cell activity. Recently, however, some

investigators have questioned the use of IFN-7 assays as definitive measurements of
the immunogenic potential of vaccine candidates.

Instead, a number of assays have been designed towards detecting actual

cytolytic function, a return to the basis of the now largely disfavored 5lCr-releas
assay. These include measurements of perforin (234, 240), granzyme (240, 241),
caspase-3 activity (242) and CD107a and b as a reflection of degranulation (243).

Additionally, several groups have explored the utility of monitoring the expression
other cytokines, including TNF-a (242, 244) and BL-2 (235). Indeed, it has been

noted that expression of cytokines such as IL-2, MIP-1/3, TNF-a and EL-4 dominate i
response to effective vaccines against HBV and tetanus, not IFN-7(245, 246).

Similarly, we must consider ultimately whether it is most appropriate to
measure CD8+ T-cell responses in general as an indicator of immunogenicity. It has
been demonstrated in the SlV/rhesus macaque model, for example, that viremia can
be controlled even in the absence of CD8+ T-cells (247, 248). Furthermore, the
recent prominent case of HIV-1 superinfection in the face of broad CD8+ T-cell
responses (249) suggests that CD8+ T-cells may not play as critical a role in
controlling infection as HIV vaccinologists previously thought.
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Thus, it is perhaps relevant to note that immune responses detected in cocultures involving DCs infected by Salmonella carrying gag vectors include CD4+
activity, as well as CD8+ (Figures 42-45). Given the likely mechanism of DNA

vaccine delivery by the invasive, intracellular bacteria, it is provocative to consi
how the system might yield MHC class II-restricted antigen presentation. We may

note, for example, that bystander DCs that internalize apoptotic cells and process t
antigens for presentation do so to both CD4+ and CD8+ T-cells (78, 99, 100).

Additionally, it is possible that the bacteria themselves express the eukaryotic va
vectors to some extent (48-53), which would certainly result in MHC class IIrestricted presentation by DCs.

Perhaps the most significant conclusion we can draw from the data herein,
therefore, is about the potency of DCs as APCs. We must accept, for example, that
very few DCs are actually reached with infection at MOIs of between 1 and 5.

Indeed, in our early studies aimed at assessing the degree of target cell expressio
reflection of functional vector transfer (See Chapters in and V), MOI was kept as
high as possible (e.g., 50-100) in order to presumably reach the maximal number of
APCs. In carrying out studies aimed at confirming antigen presentation, however, it
was appreciated that widespread expression is not equivalent to widespread

presentation; rather, DCs are largely rendered apoptotic as a consequence of bacter

invasion. Thus, in reducing MOI, we can preserve the viability of the small fraction
of DCs that are reached and invaded by the Salmonella carriers.
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T h e fact that such a small population of D C s can have such a significant effect
on T-cells is not surprising. It is well-established, in fact, that very few DCs are
required in order to activate literally thousands of T-cells (131, 250). Furthermore,
although DCs are the primary APCs of the body, they constitute <1% of the total cell
population of lymphoid tissue (71). The system of vaccine delivery evaluated in the
present study can thus serve in part to illustrate the relative functional importance of
DCs among the cells of the immune system. Moreover, the apparently successful
antigen presentation achieved here clearly suggests that targeting DCs may be
generally fruitful as a vaccine design strategy.
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Chapter VII:
Discussion

HORIZONTAL GENE TRANSFER
We have known for 60 years that functional DNA can be transferred from one

organism to another, thereby changing the genetic character of the latter (251). The

potential significance of horizontal gene transfer was not fully recognized until t

1950s, however, when bacterial multi-drug resistance emerged on a global scale. It i
now understood that horizontal (or "lateral") gene transfer has played an integral

in the evolution of bacterial genomes (252). In eukaryotic phylogeny, too, horizonta
gene transfer has apparently occurred with important evolutionary consequences.

Indeed, in the years since the first full genome sequences were made available, the
has been renewed interest in the topic (253-257).

Among unrelated species, gene transfer is infrequently observed. Rarely, for
example, have we seen spontaneous genetic exchange between prokaryotes and
eukaryotes. One well-documented case of such an anomaly is the induction of tumors

in higher plants by Agrobacterium tumefaciens, wherein a bacterial plasmid is taken
up and expressed by a plant cell (258).

The first documented evidence of direct transfer of cloned genes from bacteria
to mammalian cells was reported in 1980 (259). Expression of the plasmid gene was
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detected very infrequently, however, and appeared to be a consequence of sporadic
phagocytosis. Many years later, another group reported genetic transfer from wildtype Listeria and, to a lesser extent, Shigella to mammalian cells in vitro (67).

It was not until 1995 that attenuated bacteria were intentionally manipulated

towards the targeted delivery of DNA to eukaryotic cells (58). With this innovative
approach, a new paradigm for vaccination was born: that of a facilitated genetic
immunization, or bacterial transduction. Although integration into the target cell

genome is not involved (as with a retrovirus), we feel that the use of a "third part

deliver genetic material ultimately warrants such a term. Thus, the bacteria employe
as transducers are "vehicles," rather than "vectors," as they are not intended to
express the extra-genomic DNA they carry themselves.

BACTERIAL TRANSDUCTION
It has been known for decades by bacteriologists that intracellular bacteria
(including Mycobacteria, Chlamydia, etc., as well as Salmonella) manage to survive
within phagosomes (58, 260-263). When we first undertook to develop Salmonella as

plasmid-delivery vehicles, however, we could only speculate as to precisely how the
attenuated bacteria might accomplish the task (Chapter DI, Figure 1). Although the
mechanism of plasmid nuclear import remains a mystery, Salmonella persistence and
avoidance of lysosomal degradation within its host cell is now a well-understood
phenomenon.
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U p o n invasion, Salmonella immediately begins to shield itself from host cell
defenses by using its virulence system. It controls its intracellular niche, the
Sa/mo«e//a-containing vacuole (SCV), through the activity of various bacterial
proteins, particularly those encoded by the Salmonella Pathogenicity Island 2 locus
(SPI-2). Thus, the SCV is effectively segregated from the cell's degradative pathway
throughout the life-span of the bacteria (43).

SCVs are actively maintained by Salmonella-induced filament (Sif) A, which
is expressed by the SPI-2 Type Three Secretion System (TTSS) (42, 43).
Furthermore, the SCV is matured by the bacteria in a rab7 GTPase-dependent manner
(264, 265).

Importantly, another SPI-2 TTSS protein, SpiC, interferes with intracellular
trafficking (266), preventing phagosomal-lysosomal fusion (267). Bacterial Sif
proteins work further to prevent SCVs from proceeding to late endosomes, and even
interfere with the trafficking of non-Salmonella-containing vesicles (268, 269).
Additionally, it has specifically been revealed that SPI-2 TTSS proteins prevent all
contact between SCVs and NADPH oxidase-containing vesicles (270-272). In fact,
Salmonella uses enzymes to defend itself from oxidative stress, including superoxide
dismutase and glucose 6-phosphate dehydrogenase (43).
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Remarkably, it has recently emerged that the bacteria restore cytoskeletal
architecture once within their protected SCVs. Releasing a protein called SptP,
Salmonella reverses the cellular changes induced by its invasion (273). Finally, it is
also now known that most of the recently elucidated bacterial survival strategies
probably apply to persistence within DCs, as well as macrophages (274), though most
relevant studies have involved macrophages or macrophage cell lines.

Although we now understand that aroA- Salmonella probably remain within
vesicles until they perish intracellularly (Chapter ID, Figure 1), it remains unclear
how the plasmids they deliver are imported into the eukaryotic nucleus. Assuming
that the delivered DNA is released directly into the cytoplasm once the bacteria lyse
and the vesicular wall dissipates, it must be transported into the nucleus for
transcription to occur. With subsequent translation in the cytosol, the foreign protein
would be degraded by the proteasome, and resulting peptides shuttled into the
endoplasmic reticulum (ER) by transporters-associated-with-antigen-presentation
(TAP) for MHC class I presentation (275). This endogenous pathway is, in fact, what
is assumed to occur with conventional, untargeted DNA vaccination once the injected
plasmids are taken up by APCs (276), although it is recognized in this case that the
majority of DNA is rapidly degraded by nucleases (277).

A more appropriate, parallel model to consider would be the use of a so-called
"gene gun" for DNA vaccination. This technique involves affixing the vaccine
plasmids to gold particles before inoculation (278). Similarly, different kinds of
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D N A microparticles have been produced for use in immunization (279, 280). It is
thought that such a formulation permits direct delivery to APCs, which phagocytose

the synthetic particulate matter. Furthermore, gold or microparticles would protect
the DNA from extracellular degradation and possibly allow for mucosal
administration (279, 280). Presumably, the DNA particles enter the phagosomallysosomal pathway towards intracellular degradation. While foreign non-DNA
components could in theory be presented on MHC class D molecules, the DNA itself

is apparently imported into host cell nuclei and expressed. Encoded proteins are th
presented on MHC class I molecules (279).

The use of attenuated Salmonella to carry DNA vaccines, therefore, would
allow for similar mechanistic advantages. As an adjuvant, Salmonella not only
permits for targeted delivery through passive phagocytosis by APCs, but also by

active invasion of them. Furthermore, like microparticles, bacterial vehicles prote
DNA from premature extracellular degradation. Additionally, unlike synthetic
formulations, Salmonella bears components that have naturally evolved as
immunostimulants, including LPS as well as unmethylated sequences in bacterial
DNA (281). Finally, as discussed previously (See Chapter IV), Salmonella vehicles
allow for the mucosal administration of DNA vaccines directly to inductive sites.

In general, a system of bacterial transduction as a vaccine strategy offers
considerable promise for in vivo use. Apart from the built-in adjuvant functions

described, Salmonella is a practical tool because of its well-understood genetics a
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physiology. Indeed, live attenuated Salmonella typhi is already in use as a vaccine
against typhoid fever (27). Furthermore, infection with attenuated strains is easily
controlled with antibiotics, which provide a "safety net" in the event of any systemic
toxicity (e.g., from LPS) or reversion to wild-type virulence.

Nonetheless, certain potential complications and confounders of the approach
must also be considered. Perhaps the greatest threat to in vivo efficacy that has
emerged from in vitro experimentation is cytotoxicity: As we have seen, Salmonella
infection can induce apoptosis of APCs. In vivo, however, this effect may not prove
too much of a hindrance to effective antigen presentation, since uninfected, healthy
bystander DCs can cross-present (97-100). Furthermore, we may conclude from the
studies at hand (See Chapter VI) that there are sufficient numbers of viable DCs to
effectively present vaccine antigens to autologous T-cells, even with a very low MOI.

Another theoretical obstacle to using a Salmonella-based vaccine strategy in
vivo is the possibility of pre-existing immunity to the bacterial vehicles themselves. It
is known, however, that immunity against one strain or serotype of Salmonella does
not protect against infection with another (282, 283). Thus, an individual previously
infected or inoculated with S. typhi would not raise a memory response against S.
typhimurium. More recently, it has been seen in the context of recombinant vaccinia
vectors that pre-existing systemic immunity can be overcome by mucosal
immunization (193, 194, 284), a phenomenon that may also apply to Salmonella.
More specifically, however, investigators have found that prior immunologic
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experience with either a homologous or heterologous strain actually potentiates the
subsequent serum and mucosal antibody responses directed against foreign antigens
delivered by recombinant Salmonella (101, 238). Thus, prior exposure to Salmonella
as a pathogen or a vaccine should not preclude its subsequent use as a carrier for
DNA vaccines against other pathogens. In fact, immunologic experience with
Salmonella may enhance the subsequent response to a foreign antigen encoded by a
Salmonella-delivered vector (101).

Another concern regarding DNA vaccination in general is the risk of
integration into the host cell genome, which may promote oncogenesis. While
immunization with naked DNA has not been found to lead to genomic integration
(285), delivery of eukaryotic expression vectors by invasive E. coli (286) and
attenuated L. monocytogenes (61) has been reported to yield some chromosomal

integration in vitro. This occurrence may be a consequence of the high plasmid copy
numbers delivered to each cell by the bacteria (281). The risk for integration with

of bacterial vehicles in vivo is not yet known. It should be recalled, however, tha
transduced cells are probably fated to die, either from the apoptotic effects of
Salmonella invasion, or from CTLs that respond to their presentation of foreign
antigens (derived from the DNA vaccine or the bacterial carriers themselves). Thus,
the risks associated with chromosomal integration may be averted in vivo.
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FUTURE PROSPECTS
Developing the strategy of bacterial transduction as an approach to
vaccination would require that we reach the optimal balance of maximal
immunogenicity and minimal toxicity in vivo. The background of the carrier strain,
the type of mutation selected to achieve attenuation, and the intrinsic properties

immunogen itself would all have to be considered before proceeding to clinical tria

Any such aspect of the formulation could, alone, affect the extent and quality of t
immune response elicited (287).

Salmonella spp. are not the only bacteria that could be used in the system.

Shigella, E. coli and Listeria, for example, have also been investigated as potenti

vaccine carriers (58, 59, 61, 62, 64, 288), and the relative advantages of the diff
species should be thoroughly explored. More importantly, perhaps, genetic
modifications to the carriers could achieve greater efficacy. While Shigella and
Listeria are known to actively escape from phagosomes, Salmonella and other
candidate carriers could possibly be improved by engineering them to express an
enzyme with phagosomal escape function, such as listeriolysin (281).

In addition to strain choice, careful consideration must be given to the precise

nature of the attenuating mutation, including the level of attenuation and stabiliz
of the attenuated phenotype. An auxotrophic mutation involving the biosynthesis

pathway of purines or aromatic amino acids, for example, minimizes the virulence of
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Salmonella (289). Other consequences of such mutations, however, should also be
factored into the design of the system. It is known, in fact, that mutations affecting
virulence properties of the bacteria tend to evoke different immune responses. Thus,
different mutants may actually promote different T help patterns (287).

Nonetheless, minimizing toxicity to the host is certainly paramount in
choosing a vaccine delivery vehicle. A gram negative bacteria such as Salmonella
could theoretically induce septic shock if it is not carefully modified. Thus, as a tool
in cancer therapy, S. typhimurium mutants have been engineered to avoid inducing a
systemic TNF-Q! based inflammatory response while retaining hyperinvasive
properties thought to be desirable for efficacy (290).

Dosing and vaccination schedule would also have to be experimentally
determined. What is the minimum effective dose of bacteria needed to ensure in vivo
transduction and antigen presentation? Does the priming need to be boosted? What
are the in vivo kinetics of bacterial growth and persistence? (Is the administration of
antibiotics necessary for timely elimination of the vehicles?)

More important, of course, is the need to choose antigens wisely. A DNA
vaccine against HIV-1, for example, is a significant challenge to design, even without
considering method of delivery (13, 14). What permutation of viral genes should be
included? (Should they be "codon-optimized" for increased eukaryotic expression
and Rev-independent nuclear export?) Which vector backbone should be employed,
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and with which eukaryotic promoter? Is a leader sequence necessary? In general,
steps should be taken to maximize gene expression in situ and augment DNA

vaccine-elicited immune responses, in addition to the adjuvanticity provided by the
bacterial carriers.

Development would also require in vivo studies prior to clinical trials. As we
have seen, however, use of the murine model is limited and confounded by the
cytotoxicity of S. typhimurium towards murine DCs. For the purpose of evaluating
vaccine candidates against HIV-1, then, it would instead be more sensible to employ
the rhesus macaque/SIV system. Although this non-human primate model has been

very important for pre-clinical challenge studies of ADDS vaccines, it has recently
been pointed out that improvements are required to more closely reflect the actual
biological circumstances of HIV-1 infection in humans (4). Bearing this need in
mind, however, it would indeed be useful to attempt in vivo immunization using
bacterial transduction in macaques.

In general, we feel that the use of Salmonella carriers to deliver DNA vaccines
constitutes a powerful tool with which to improve the efficiency and augment the
immunogenicity of basic genetic immunization. Because of its simplicity and

economy, DNA vaccination has been especially attractive as a strategy for use in th
developing world. With the additional advantage of oral administration, therefore,

potential utility is enhanced even further. Indeed, the system explored in this rep
offers an excellent prototypical design from which to base other such technologies
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genetic delivery. A s an approach to immunization, specifically, it m a y predict the
general future direction of vaccinology.

129

References

1.

2.
3.

4.
5.

6.
7.
8.
9.

10.

11.

12.

13.
14.

15.

U N A I D S / W H O . 2003. A I D S Epidemic Update. Joint United Nations
Programme on HIV/ADDS (UNAIDS), World Health Organization ( W H O ) ,
Geneva.
Robinson, H. L. 2002. N e w hope for an A I D S vaccine. Nat Rev Immunol
2:239.
Desrosiers, R. C. 2004. W h y an HIV-1 Vaccine is Not Currently Within our
Grasp. In 11th Conference on Retroviruses and Opportunistic Infections, San
Francisco.
Feinberg, M . B., and J. P. Moore. 2002. AIDS vaccine models: challenging
challenge viruses. Nat M e d 8:207.
Heeney, J. L., P. Beverley, A. McMichael, G. Shearer, J. Strominger, B.
Wahren, J. Weber, and F. Gotch. 1999. Immune correlates of protection from
H I V and A I D S - more answers but yet more questions. Immunol Today
20:247.
McMichael, A. J., and T. Hanke. 2003. HIV vaccines 1983-2003. Nat M e d
9:874.
Mascola, J. R., and G. J. Nabel. 2001. Vaccines for the prevention of HIV-1
disease. Curr Opin Immunol 13:489.
Letvin, N. L. 1998. Progress in the development of an HIV-1 vaccine. Science
280:1875.
Hasan, U. A., A. M . Abai, D. R. Harper, B. W . Wren, and W . J. Morrow.
1999. Nucleic acid immunization: concepts and techniques associated with
third generation vaccines. J Immunol Methods 229:1.
Corr, M., A. von D a m m , D. J. Lee, and H. Tighe. 1999. In vivo priming by
D N A injection occurs predominantly by antigen transfer. J Immunol
163:4721.
Kumaraguru, U., R. J. Rouse, S. K. Nair, B. D. Bruce, and B. T. Rouse. 2000.
Involvement of an ATP-dependent peptide chaperone in cross-presentation
after D N A immunization. J Immunol 165:750.
Dupuis, M., K. Denis-Mize, C. W o o , C. Goldbeck, M . J. Selby, M . Chen, G.
R. Otten, J. B. Ulmer, J. J. Donnelly, G. Ott, and D. M . McDonald. 2000.
Distribution of D N A vaccines determines their immunogenicity after
intramuscular injection in mice. J Immunol 165:2850.
Barouch, D. H., and N. L. Letvin. 2000. D N A vaccination for HIV-1 and SIV.
Intervirology 43:282.
Muthumani, K., S. Kudchodkar, D. Zhang, M . L. Bagarazzi, J. J. Kim, J. D.
Boyer, V. Ayyavoo, G. N. Pavlakis, and D. B. Weiner. 2002. Issues for
improving multiplasmid D N A vaccines for HIV-1. Vaccine 20:1999.
Blume, S., and I. Geesink. 2000. A brief history of polio vaccines. Science
288:1593.

130

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.
26.
27.
28.
29.
30.

31.
32.

Hone, D. M., G. K. Lewis, M . Beier, A. Harris, T. McDaniels, and T. R.
Fouts. 1994. Expression of human immunodeficiency virus antigens in an
attenuated Salmonella typhi vector vaccine. Dev Biol Stand 82:159.
Fouts, T. R., G. K. Lewis, and D. M . Hone. 1995. Construction and
characterization of a Salmonella typhi-based human immunodeficiency virus
type 1 vector vaccine. Vaccine 13:561.
Fouts, T. R., R. G. Tuskan, S. Chada, D. M . Hone, and G. K. Lewis. 1995.
Construction and immunogenicity of Salmonella typhimurium vaccine vectors
that express HIV-1 gpl20. Vaccine 13:1697.
Tzschaschel, B. D., C. A. Guzman, K. N. Timmis, and V. de Lorenzo. 1996.
A n Escherichia coli hemolysin transport system-based vector for the export of
polypeptides: export of Shiga-like toxin DeB subunit by Salmonella
typhimurium aroA. Nat Biotechnol 14:765.
Hess, J., I. Gentschev, D. Miko, M . Welzel, C. Ladel, W . Goebel, and S. H.
Kaufrnann. 1996. Superior efficacy of secreted over somatic antigen display in
recombinant Salmonella vaccine induced protection against listeriosis. Proc
Natl Acad Sci U S A 93:1458.
Cattozzo, E. M., B. A. Stocker, A. Radaelli, C. D e Giuli Morghen, and M .
Tognon. 1997. Expression and immunogenicity of V 3 loop epitopes of HIV-1,
isolates S C and W M J 2 , inserted in Salmonella flagellin. J Biotechnol 56:191.
Russmann, H., H. Shams, F. Poblete, Y. Fu, J. E. Galan, and R. O. Donis.
1998. Delivery of epitopes by the Salmonella type ID secretion system for
vaccine development. Science 281:565.
Dalla Pozza, T., H. Yan, D. Meek, C. A. Guzman, and M . J. Walker. 1998.
Construction and characterisation of Salmonella typhimurium aroA
simultaneously expressing thefivepertussis toxin subunits. Vaccine 16:522.
Steger, K. K., P. J. Valentine, F. Heffron, M . So, and C. D. Pauza. 1999.
Recombinant, attenuated Salmonella typhimurium stimulate
lymphoproliferative responses to SIV capsid antigen in rhesus macaques.
Vaccine 17:923.
Newton, S. M., C. O. Jacob, and B. A. Stocker. 1989. Immune response to
cholera toxin epitope inserted in Salmonella flagellin. Science 244:70.
Vogel, F. R. 1998. Adjuvants in perspective. Dev Biol Stand 92:241.
2004. Physicians' Desk Reference. Thomson P D R , Montvale.
Eriksson, K., and J. Holmgren. 2002. Recent advances in mucosal vaccines
and adjuvants. Curr Opin Immunol 14:666.
Dietrich, G., M . Griot-Wenk, I. C. Metcalfe, A. B. Lang, and J. F. Viret. 2003.
Experience with registered mucosal vaccines. Vaccine 21:678.
Holmgren, J., C. Czerkinsky, K. Eriksson, and A. Mharandi. 2003. Mucosal
immunisation and adjuvants: a brief overview of recent advances and
challenges. Vaccine 21 :S89.
Strober, W., and R. L. Coffman. 1997. Tolerance and immunity in the
mucosal immune system. Introduction. Res Immunol 148:489.
Andre, S., B. Seed, J. Eberle, W . Schraut, A. Bultmann, and J. Haas. 1998.
Increased immune response elicited by D N A vaccination with a synthetic
gpl20 sequence with optimized codon usage. J Virol 72:1497.

131

33.

34.

35.
36.

37.
38.

39.

40.

41.
42.
43.

44.

45.
46.

Al.

48.

Uchijima, M., A. Yoshida, T. Nagata, and Y. Koide. 1998. Optimization of
codon usage of plasmid D N A vaccine is required for the effective M H C class
I-restricted T cell responses against an intracellular bacterium. J Immunol
161:5594.
Wolf, E., and P. S. Kim. 1999. Combinatorial codons: a computer program to
approximate amino acid probabilities with biased nucleotide usage. Protein
Sci 8:680.
Kozak, M . 1987. At least six nucleotides preceding the A U G initiator codon
enhance translation in mammalian cells. J Mol Biol 196:947.
Golden, A., D. A. Austen, M . R. van Schravendijk, B. J. Sullivan, E. S.
Kawasaki, and M . S. Osburne. 1998. Effect of promoters and signal sequences
on the production of secreted HIV-1 gpl20 protein in the baculovirus system.
Protein Expr Purif 14:8.
Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene 108:193.
Chen, Z., Y. Sahashi, K. Matsuo, H. Asanuma, H. Takahashi, T. Iwasaki, Y.
Suzuki, C. Aizawa, T. Kurata, and S. Tamura. 1998. Comparison of the ability
of viral protein-expressing plasmid D N A s to protect against influenza.
Vaccine 16:1544.
Oikawa, Y., A. Shimada, A. Kasuga, J. Morimoto, T. Osaki, H. Tahara, T.
Miyazaki, F. Tashiro, E. Yamato, J. Miyazaki, and T. Saruta. 2003. Systemic
administration of IL-18 promotes diabetes development in young nonobese
diabetic mice. J Immunol 171:5865.
Kodihalli, S., J. R. Haynes, H. L. Robinson, and R. G. Webster. 1997. Crossprotection among lethal H 5 N 2 influenza viruses induced by D N A vaccine to
the hemagglutinin. J Virol 71:3391.
Dangl, J. L. 2003. Molecular call-and-response: how Salmonella learns the
gospel from its host. Trends Microbiol 11:245.
Amer, A. O., and M . S. Swanson. 2002. A phagosome of one's own: a
microbial guide to life in the macrophage. Curr Opin Microbiol 5:56.
Linehan, S. A., and D. W . Holden. 2003. The interplay between Salmonella
typhimurium and its macrophage host—what can it teach us about innate
immunity? Immunol Lett 85:183.
Mizel, S. B., L. S. Kucera, S. H. Richardson, F. Ciacci, and N. P. Iyer. 1995.
Regulation of macrophage activation and human immunodeficiency virus
production by invasive Salmonella strains. Infect Immun 63:1820.
Hoiseth, S. K., and B. A. Stocker. 1981. Aromatic-dependent Salmonella
typhimurium are non-virulent and effective as live vaccines. Nature 291:238.
Darji, A., C. A. Guzman, B. Gerstel, P. Wachholz, K. N. Timmis, J. Wehland,
T. Chakraborty, and S. Weiss. 1997. Oral somatic transgene vaccination using
attenuated S. typhimurium. Cell 91:765.
Stocker, B. A. 2000. Aromatic-dependent salmonella as anti-bacterial
vaccines and as presenters of heterologous antigens or of D N A encoding
them. J Biotechnol 83:45.
Schnetz, K., and B. Rak. 1992. IS5: a mobile enhancer of transcription in
Escherichia coli. Proc Natl Acad Sci U S A 89:1244.

132

49.

50.

51.

52.

53.
54.
55.
56.

57.

58.

59.
60.

61.

62.

63.

Rosfjord, E., K. Lamb, and A. Rizzino. 1994. Cryptic promoter activity within
the backbone of a plasmid commonly used to prepare promoter/reporter gene
constructs. In Vitro Cell Dev Biol Anim 30A:477.
Takahashi, N., H. Hotta, and M . H o m m a . 1991. Activation and suppression of
a cryptic promoter in the intron of the human melanoma-associated M E 4 9 1
antigen gene. Jpn J Cancer Res 82:1239.
Reynolds, A. E., S. Mahadevan, S. F. LeGrice, and A. Wright. 1986.
Enhancement of bacterial gene expression by insertion elements or by
mutation in a C A P - c A M P binding site. J Mol Biol 191:85.
Lepage, P., D. A. Underhill, and P. Gros. 1995. Activation of a M M T V / m d r 3
fusion transcript from a cryptic viral promoter is stimulated by mdr-derived
sequences located in intron I. Virology 210:244.
Miller, W . G., and R. W . Simons. 1990. D N A from diverse sources manifests
cryptic low-level transcription in Escherichia coli. Mol Microbiol 4:881.
Breathnach, R., and P. Chambon. 1981. Organization and expression of
eucaryotic split genes coding for proteins. Annu Rev Biochem 50:349.
Nevins, J. R. 1983. The pathway of eukaryotic m R N A formation. Annu Rev
Biochem 52:441.
Rocancourt, D., C. Bonnerot, H. Jouin, M . Emerman, and J. F. Nicolas. 1990.
Activation of a beta-galactosidase recombinant provirus: application to
titration of human immunodeficiency virus (HIV) and HIV-infected cells. J
Virol 64:2660.
Muesing, M . A., D. H. Smith, and D. J. Capon. 1987. Regulation of m R N A
accumulation by a human immunodeficiency virus trans-activator protein.
Cell 48:691.
Sizemore, D. R., A. A. Branstrom, and J. C. Sadoff. 1995. Attenuated Shigella
as a D N A delivery vehicle for DNA-mediated immunization. Science
270:299.
Sizemore, D. R., A. A. Branstrom, and J. C. Sadoff. 1997. Attenuated bacteria
as a D N A delivery vehicle for DNA-mediated immunization. Vaccine 15:804.
Paglia, P., E. Medina, I. Arioli, C. A. Guzman, and M . P. Colombo. 1998.
Gene transfer in dendritic cells, induced by oral D N A vaccination with
Salmonella typhimurium, results in protective immunity against a murine
fibrosarcoma. Blood 92:3172.
Dietrich, G., A. Bubert, I. Gentschev, Z. Sokolovic, A. Simm, A. Catic, S. H.
Kaufrnann, J. Hess, A. A. Szalay, and W . Goebel. 1998. Delivery of antigenencoding plasmid D N A into the cytosol of macrophages by attenuated suicide
Listeria monocytogenes. Nat Biotechnol 16:181.
Fennelly, G. J., S. A. Khan, M . A. Abadi, T. F. Wild, and B. R. Bloom. 1999.
Mucosal D N A vaccine immunization against measles with a highly attenuated
Shigellaflexnerivector. J Immunol 162:1603.
Xiang, R., H. N. Lode, T. H. Chao, J. M . Ruehlmann, C. S. Dolman, F.
Rodriguez, J. L. Whitton, W . W . Overwijk, N. P. Restifo, and R. A. Reisfeld.
2000. .An autologous oral D N A vaccine protects against murine melanoma.
Proc Natl Acad Sci U S A 97:5492.

133

64.

65.

66.

67.

68.

69.
70.
71.
72.

73.
IA.

75.

76.

11.

78.

Shata, M . T., and D. M . Hone. 2001. Vaccination with a Shigella D N A
vaccine vector induces antigen-specific CD8(+) T cells and antiviral
protective immunity. J Virol 75:9665.
Wedemeyer, H., S. Gagneten, A. Davis, R. Bartenschlager, S. Feinstone, and
B. Rehermann. 2001. Oral immunization with HCV-NS3-transformed
Salmonella: induction of HCV-specific C T L in a transgenic mouse model.
Gastroenterology 121:1158.
Shiau, A. L., Y. L. Chen, C. Y. Liao, Y. S. Huang, and C. L. W u . 2001.
Prothymosin alpha enhances protective immune responses induced by oral
D N A vaccination against pseudorabies delivered by Salmonella choleraesuis.
Vaccine 19:3947.
Grillot-Courvalin, C , S. Goussard, and P. Courvalin. 2002. Wild-type
intracellular bacteria deliver D N A into mammalian cells. Cell Microbiol
4:177.
Cochlovius, B., M . J. Stassar, M . W . Schreurs, A. Benner, and G. J. Adema.
2002. Oral D N A vaccination: antigen uptake and presentation by dendritic
cells elicits protective immunity. Immunol Lett 80:89.
Unanue, E. R. 1984. Anti gen-presenting function of the macrophage. Annu
Rev Immunol 2:395.
Janeway, C. A., and P. Travers. 1997. Immunobiology: The Immune System
in Health and Disease. Garland Publishing Inc., N e w York.
Abbas, A. K., A. H. Lichtman, and J. S. Pober. 1997. Cellular and Molecular
Immunology. W . B. Saunders Company, Philadelphia.
Monack, D. M., B. Raupach, A. E. Hromockyj, and S. Falkow. 1996.
Salmonella typhimurium invasion induces apoptosis in infected macrophages.
Proc Natl Acad Sci U S A 93:9833.
Chen, L. M., K. Kaniga, and J. E. Galan. 1996. Salmonella spp. are cytotoxic
for cultured macrophages. M o l Microbiol 21:1101.
Hersh, D., D. M . Monack, M . R. Smith, N. Ghori, S. Falkow, and A.
Zychlinsky. 1999. The Salmonella invasin SipB induces macrophage
apoptosis by binding to caspase-1. Proc Natl Acad Sci U S A 96:2396.
Lundberg, U., U. Vinatzer, D. Berdnik, A. von Gabain, and M . Baccarini.
1999. Growth phase-regulated induction of Salmonella-induced macrophage
apoptosis correlates with transient expression of SPI-1 genes. J Bacteriol
181:3433.
van der Velden, A. W., S. W . Lindgren, M . J. Worley, and F. Heffron. 2000.
Salmonella pathogenicity island 1-independent induction of apoptosis in
infected macrophages by Salmonella enterica serotype typhimurium. Infect
Immun 68:5702.
Jesenberger, V., K. J. Procyk, J. Yuan, S. Reipert, and M . Baccarini. 2000.
Salmonella-induced caspase-2 activation in macrophages: a novel mechanism
in pathogen-mediated apoptosis. J Exp M e d 192:1035.
Yrlid, U., and M . J. Wick. 2000. Salmonella-induced apoptosis of infected
macrophages results in presentation of a bacteria-encoded antigen after uptake
by bystander dendritic cells. J Exp M e d 191:613.

134

79.

80.

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

Monack, D. M., D. Hersh, N. Ghori, D. Bouley, A. Zychlinsky, and S.
Falkow. 2000. Salmonella exploits caspase-1 to colonize Peyer's patches in a
murine typhoid model. J Exp M e d 192:249.
Cerquetti, M . C , N. B. Goren, A. J. Ropolo, D. Grasso, M . N.
Giacomodonato, and M . I. Vaccaro. 2002. Nitric oxide and apoptosis induced
in Peyer's patches by attenuated strains of Salmonella enterica serovar
Enteritidis. Infect Immun 70:964.
Paesold, G., D. G. Guiney, L. Eckmann, and M . F. Kagnoff. 2002. Genes in
the Salmonella pathogenicity island 2 and the Salmonella virulence plasmid
are essential for Salmonella-induced apoptosis in intestinal epithelial cells.
Cell Microbiol 4:771.
Forsberg, M., R. Blomgran, M . Lerm, E. Sarndahl, S. M . Sebti, A. Hamilton,
O. Stendahl, and L. Zheng. 2003. Differential effects of invasion by and
phagocytosis of Salmonella typhimurium on apoptosis in human
macrophages: potential role of Rho-GTPases and Akt. J Leukoc Biol 74:620.
Zhou, X., N. Mantis, X. R. Zhang, D. A. Potoka, S. C. Watkins, and H. R.
Ford. 2000. Salmonella typhimurium induces apoptosis in human monocytederived macrophages. Microbiol Immunol 44:987.
Libby, S. J., M . Lesnick, P. Hasegawa, E. Weidenhammer, and D. G. Guiney.
2000. The Salmonella virulence plasmid spv genes are required for
cytopathology in human monocyte-derived macrophages. Cell Microbiol
2:49.
Monack, D. M., C. S. Detweiler, and S. Falkow. 2001. Salmonella
pathogenicity island 2-dependent macrophage death is mediated in part by the
host cysteine protease caspase-1. Cell Microbiol 3:825.
Schwan, W . R., and D. J. Kopecko. 1997. Uptake of pathogenic intracellular
bacteria into human and murine macrophages downregulates the eukaryotic
26S protease complex ATPase gene. Infect Immun 65:4754.
Malo, D., K. Vogan, S. Vidal, J. Hu, M . Cellier, E. Schurr, A. Fuks, N.
Bumstead, K. Morgan, and P. Gros. 1994. Haplotype mapping and sequence
analysis of the mouse Nramp gene predict susceptibility to infection with
intracellular parasites. Genomics 23:51.
Fayolle, C , D. O'Callaghan, P. Martineau, A. Charbit, J. M . Clement, M .
Hofhung, and C. Leclerc. 1994. Genetic control of antibody responses induced
against an antigen delivered by recombinant attenuated Salmonella
typhimurium. Infect Immun 62:4310.
Cellier, M., G. Govoni, S. Vidal, T. Kwan, N. Groulx, J. Liu, F. Sanchez, E.
Skamene, E. Schurr, and P. Gros. 1994. H u m a n natural resistance-associated
macrophage protein: c D N A cloning, chromosomal mapping, genomic
organization, and tissue-specific expression. J Exp M e d 180:1741.
Eckmann, L., J. Fierer, and M . F. Kagnoff. 1996. Genetically resistant (Ityr)
and susceptible (Itys) congenic mouse strains show similar cytokine responses
following infection with Salmonella dublin. J Immunol 156:2894.
Gautier, A. V., I. Lantier, and F. Lantier. 1998. Mouse susceptibility to
infection by the Salmonella abortusovis vaccine strain Rv6 is controlled by

135

92.
93.

94.

95.

96.

97.

98.

99.

100.

101.
102.

103.

the Ity/Nramp 1 gene and influences the antibody but not the complement
responses. Microb Pathog 24:47.
Govoni, G., and P. Gros. 1998. Macrophage N R A M P 1 and its role in
resistance to microbial infections. Inflamm Res 47:277.
Araujo, L. M., O. G. Ribeiro, M . Siqueira, M . D e Franco, N. Starobinas, S.
Massa, W . H. Cabrera, D. Mouton, M . Seman, and O. M . Ibanez. 1998. Innate
resistance to infection by intracellular bacterial pathogens differs in mice
selected for maximal or minimal acute inflammatory response. Eur J Immunol
28:2913.
Zaharik, M . L., B. A. Vallance, J. L. Puente, P. Gros, and B. B. Finlay. 2002.
Host-pathogen interactions: Host resistance factor Nrampl up-regulates the
expression of Salmonella pathogenicity island-2 virulence genes. Proc Natl
Acad Sci U S A 99:15705.
Cuellar-Mata, P., N. Jabado, J. Liu, W . Furuya, B. B. Finlay, P. Gros, and S.
Grinstein. 2002. Nrampl modifies the fusion of Salmonella typhimuriumcontaining vacuoles with cellular endomembranes in macrophages. J Biol
Chem 277:2258.
Schwan, W . R., X. Z. Huang, L. Hu, and D. J. Kopecko. 2000. Differential
bacterial survival, replication, and apoptosis-inducing ability of Salmonella
serovars within human and murine macrophages. Infect Immun 68:1005.
Albert, M . L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire
antigen from apoptotic cells and induce class I-restricted CTLs. Nature
392:86.
Albert, M . L., S. F. Pearce, L. M . Francisco, B. Sauter, P. Roy, R. L.
Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose
apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to
cytotoxic T lymphocytes. J Exp M e d 188:1359.
Rovere, P., C. Vallinoto, A. Bondanza, M . C. Crosti, M . Rescigno, P.
Ricciardi-Castagnoli, C. Rugarli, and A. A. Manfredi. 1998. Bystander
apoptosis triggers dendritic cell maturation and antigen-presenting function. J
Immunol 161:4467.
Iyoda, T., S. Shimoyama, K. Liu, Y. Omatsu, Y. Akiyama, Y. Maeda, K.
Takahara, R. M . Steinman, and K. Inaba. 2002. The C D 8 + dendritic cell
subset selectively endocytoses dying cells in culture and in vivo. J Exp M e d
195:1289.
Kagnoff, M . F., and H. Kiyono. 1996. Essentials of Mucosal Immunology.
Academic Press, San Diego.
Rey, J., N. Garin, F. Spertini, and B. Corthesy. 2004. Targeting of secretory
IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells.
J Immunol 172:3026.
Belyakov, I. M., J. D. Ahlers, B. Y. Brandwein, P. Earl, B. L. Kelsall, B.
Moss, W . Strober, and J. A. Berzofsky. 1998. The importance of local
mucosal HlV-specific CD8(+) cytotoxic T lymphocytes for resistance to
mucosal viral transmission in mice and enhancement of resistance by local
administration of EL-12 .J Clin Invest 102:2072.

136

104.
105.
106.

107.

108.
109.
110.
111.
112.
113.

114.

115.
116.

111.

118.
119.

120.

Neutra, M . R. 1998. H I V transmission and immune protection at mucosal
surfaces. Adv Exp M e d Biol 452:169.
Lehner, T., L. Bergmeier, Y. Wang, L. Tao, and E. Mitchell. 1999. A rational
basis for mucosal vaccination against HIV infection. Immunol Rev 170:183.
Jones, B. D., N. Ghori, and S. Falkow. 1994. Salmonella typhimurium
initiates murine infection by penetrating and destroying the specialized
epithelial M cells of the Peyer's patches. J Exp M e d 180:15.
Neutra, M . R., E. Pringault, and J. P. Kraehenbuhl. 1996. Antigen sampling
across epithelial barriers and induction of mucosal immune responses. Annu
Rev Immunol 14:275.
Neutra, M . R., A. Frey, and J. P. Kraehenbuhl. 1996. Epithelial M cells:
gateways for mucosal infection and immunization. Cell 86:345.
Sirard, J. C , F. Niedergang, and J. P. Kraehenbuhl. 1999. Live attenuated
Salmonella: a paradigm of mucosal vaccines. Immunol Rev 171:5.
Frey, A., and M . R. Neutra. 1997. Targeting of mucosal vaccines to Peyer's
patch M cells. Behring Inst Mitt:3 76.
Hathaway, L. J., and J. P. Kraehenbuhl. 2000. The role o f M cells in mucosal
immunity. Cell M o l Life Sci 57:323.
Wang, X., D. M . Hone, A. Haddad, M . T. Shata, and D. W . Pascual. 2003. M
cell D N A vaccination for C T L immunity to HIV. J Immunol 171:4717.
Hogquist, K. A., S. C. Jameson, W . R. Heath, J. L. Howard, M . J. Bevan, and
F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive
selection. Cell 76:17.
Barnden, M . J., J. Allison, W . R. Heath, and F. R. Carbone. 1998. Defective
T C R expression in transgenic mice constructed using cDNA-based alpha- and
beta-chain genes under the control of heterologous regulatory elements.
Immunol Cell Biol 76:34.
Yrlid, U., M . Svensson, A. Kirby, and M . J. Wick. 2001. Antigen-presenting
cells and anti-Salmonella immunity. Microbes Infect 3:1239.
Dreher, D., M . Kok, L. Cochand, S. G. Kiama, P. Gehr, J. C. Pechere, and L.
P. Nicod. 2001. Genetic background of attenuated Salmonella typhimurium
has profound influence on infection and cytokine patterns in human dendritic
cells. J Leukoc Biol 69:583.
Dreher, D., M . Kok, C. Obregon, S. G. Kiama, P. Gehr, and L. P. Nicod.
2002. Salmonella virulence factor SipB induces activation and release of IL18 in human dendritic cells. J Leukoc Biol 72:743.
Rescigno, M., and P. Borrow. 2001. The host-pathogen interaction: new
themes from dendritic cell biology. Cell 106:267.
Rescigno, M., F. Granucci, S. Citterio, M . Foti, and P. Ricciardi-Castagnoli.
1999. Coordinated events during bacteria-induced D C maturation. Immunol
Today 20:200.
Svensson, M., C. Johansson, and M . J. Wick. 2000. Salmonella enterica
serovar typhimurium-induced maturation of bone marrow-derived dendritic
cells. Infect Immun 68:6311.

137

121.

122.

123.

124.

125.

126.

127.

128.
129.

130.
131.
132.
133.

134.

Visintin, A., A. Mazzoni, J. H. Spitzer, D. H. Wyllie, S. K. Dower, and D. M .
Segal. 2001. Regulation of Toll-like receptors in human monocytes and
dendritic cells. J Immunol 166:249.
Hertz, C. J., S. M . Kiertscher, P. J. Godowski, D. A. Bouis, M . V. Norgard,
M . D. Roth, and R. L. Modlin. 2001. Microbial lipopeptides stimulate
dendritic cell maturation via Toll-like receptor 2. J Immunol 166:2444.
Kaisho, T., O. Takeuchi, T. Kawai, K. Hoshino, and S. Akira. 2001.
Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol
166:5688.
Rescigno, M., M . Urbano, M . Rimoldi, B. Valzasina, G. Rotta, F. Granucci,
and P. Ricciardi-Castagnoli. 2002. Toll-like receptor 4 is not required for the
full maturation of dendritic cells or for the degradation of Gram-negative
bacteria. Eur J Immunol 32:2800.
Hofer, S., M . Rescigno, F. Granucci, S. Citterio, M . Francolini, and P.
Ricciardi-Castagnoli. 2001. Differential activation of NF-kappa B subunits in
dendritic cells in response to Gram-negative bacteria and to
lipopolysaccharide. Microbes Infect 3:259.
Shata, M . T., M . S. Reitz, Jr., A. L. DeVico, G. K. Lewis, and D. M . Hone.
2001. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after
intragastric vaccination with a Salmonella Env D N A vaccine vector. Vaccine
20:623.
Niethammer, A. G., R. Xiang, J. C. Becker, H. Wodrich, U. Peril, G. Karsten,
B. P. Eliceiri, and R. A. Reisfeld. 2002. A D N A vaccine against V E G F
receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat M e d
8:1369.
Huang, Y. 2002. unpublished data.
Czerkinsky, C , F. Anjuere, J. R. McGhee, A. George-Chandy, J. Holmgren,
M . P. Kieny, K. Fujiyashi, J. F. Mestecky, V. Pierrefite-Carle, C. Rask, and J.
B. Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine
development. Immunol Rev 170:197.
Williamson, E., G. M . Westrich, and J. L. Viney. 1999. Modulating dendritic
cells to optimize mucosal immunization protocols. J Immunol 163:3668.
Banchereau, J., and R. M . Steinman. 1998. Dendritic cells and the control of
immunity. Nature 392:245.
Moser, M . 2003. Dendritic cells in immunity and tolerance-do they display
opposite functions? Immunity 19:5.
Huang, F. P., N. Piatt, M . Wykes, J. R. Major, T. J. Powell, C. D. Jenkins, and
G. G. MacPherson. 2000. A discrete subpopulation of dendritic cells
transports apoptotic intestinal epithelial cells to T cell areas of mesenteric
lymph nodes. J Exp M e d 191:435.
Makala, L. H., J. C. Reyes, Y. Nishikawa, Y. Tsushima, X. Xuan, X. Huang,
B. Battsetseg, T. Matsuo, and H. Nagasawa. 2003. Phenotype and function of
murine discrete Peyer's patch macrophage derived - dendritic cells. J Vet M e d
Sci 65:491.

138

135.

136.

137.

138.

139.
140.

141.

142.

143.

144.

145.

146.

147.
148.

Steinman, R. M., S. Turley, I. Mellman, and K. Inaba. 2000. The induction of
tolerance by dendritic cells that have captured apoptotic cells. J Exp M e d
191:411.
Sauter, B., M . L. Albert, L. Francisco, M . Larsson, S. Somersan, and N.
Bhardwaj. 2000. Consequences of cell death: exposure to necrotic tumor cells,
but not primary tissue cells or apoptotic cells, induces the maturation of
immunostimulatory dendritic cells. J Exp M e d 191:423.
Nussenzweig, M . C , and R. M . Steinman. 1980. Contribution of dendritic
cells to stimulation of the murine syngeneic mixed leukocyte reaction. J Exp
M e d 151:1196.
Miyazaki, H., A. Ito, and T. Osawa. 1988. Enhancement of antigen-presenting
function of dendritic cells with culture supernatants of mouse peritoneal
macrophages stimulated with certain particulate substances. Microbiol
Immunol 32:1033.
Schafer, R., C. A. Nacy, and T. K. Eisenstein. 1988. Induction of activated
macrophages in C3H/HeJ mice by avirulent Salmonella. J Immunol 140:1638.
Wick, M . J., J. D. Pfeifer, K. A. Findlay, C. V. Harding, and S. J. Normark.
1993. Compartmentalization of defined epitopes expressed in Escherichia coli
has only a minor influence on efficiency of phagocytic processing for
presentation by class I and class D major histocompatibility complex
molecules to T cells. Infect Immun 61:4848.
Wick, M . J., C. V. Harding, S. J. Normark, and J. D. Pfeifer. 1994. Parameters
that influence the efficiency of processing antigenic epitopes expressed in
Salmonella typhimurium. Infect Immun 62:4542.
Rezzani, R., L. Rodella, G. Zauli, L. Caimi, and M . Vitale. 1999. Mouse
peritoneal cells as a reservoir of late dendritic cell progenitors. Br J Haematol
104:111.
Makala, L. H., Y. Nishikawa, T. Kamada, X. Xuan, and H. Nagasawa. 2001.
Antigen presentation by murine peritoneal cavity macrophage-derived
dendritic cells. Pathobiology 69:104.
Makala, L. H., Y. Nishikawa, M . Mishima, N. Inoue, X. Xuan, H. Suzuki, K.
Fujisaki, T. Mikami, and H. Nagasawa. 2002. Phenotype and function of
murine peritoneal cavity macrophage derived-dendritic cells. J Vet M e d Sci
64:813.
Gao, J. X., X. Liu, J. W e n , H. Zhang, J. Durbin, Y. Liu, and P. Zheng. 2003.
Differentiation of monocytic cell clones into C D 8 alpha+ dendritic cells (DC)
suggests that monocytes can be direct precursors for both C D 8 alpha+ and
C D 8 alpha- D C in the mouse. J Immunol 170:5927.
Peril, U., H. Wodrich, J. M . Ruehlmann, S. D. Gillies, H. N. Lode, and R. A.
Reisfeld. 2003. Immunotherapy with a posttranscriptionally modified D N A
vaccine induces complete protection against metastatic neuroblastoma. Blood
101:649.
Fouts, T. 2002. personal communication.
Rescigno, M., S. Citterio, C. Thery, M . Rittig, D. Medaglini, G. Pozzi, S.
Amigorena, and P. Ricciardi-Castagnoli. 1998. Bacteria-induced neo-

139

149.

150.

151.

152.
153.

154.

155.

156.

157.

158.

159.
160.

161.

biosynthesis, stabilization, and surface expression of functional class I
molecules in mouse dendritic cells. Proc Natl Acad Sci U S A 95:5229.
Yrlid, U., M . Svensson, A. Hakansson, B. J. Chambers, H. G. Ljunggren, and
M . J. Wick. 2001. In vivo activation of dendritic cells and T cells during
Salmonella enterica serovar Typhimurium infection. Infect Immun 69:5726.
Yrlid, U., M . Svensson, C. Johansson, and M . J. Wick. 2000. Salmonella
infection of bone marrow-derived macrophages and dendritic cells: influence
on antigen presentation and initiating an immune response. F E M S Immunol
M e d Microbiol 27:313.
Yrlid, U., and M . J. Wick. 2002. .^\ntigen presentation capacity and cytokine
production by murine splenic dendritic cell subsets upon Salmonella
encounter. J Immunol 169:108.
Mellman, I., and R. M . Steinman. 2001. Dendritic cells: specialized and
regulated antigen processing machines. Cell 106:255.
Niedergang, F., J. C. Sirard, C. T. Blanc, and J. P. Kraehenbuhl. 2000. Entry
and survival of Salmonella typhimurium in dendritic cells and presentation of
recombinant antigens do not require macrophage-specific virulence factors.
Proc Natl Acad Sci U S A 97:14650.
Rotta, G., E. W . Edwards, S. Sangaletti, C. Bennett, S. Ronzoni, M . P.
Colombo, R. M . Steinman, G. J. Randolph, and M . Rescigno. 2003.
Lipopolysaccharide or whole bacteria block the conversion of inflammatory
monocytes into dendritic cells in vivo. J Exp M e d 198:1253.
Rescigno, M., B. Valzasina, R. Bonasio, M . Urbano, and P. RicciardiCastagnoli. 2001. Dendritic cells, loaded with recombinant bacteria
expressing tumor antigens, induce a protective tumor-specific response. Clin
Cancer Res 7:865s.
D e Smedt, T., B. Pajak, E. Muraille, L. Lespagnard, E. Heinen, P. D e
Baetselier, J. Urbain, O. Leo, and M . Moser. 1996. Regulation of dendritic
cell numbers and maturation by lipopolysaccharide in vivo. J Exp M e d
184:1413.
Vermaelen, K. Y., I. Carro-Muino, B. N. Lambrecht, and R. A. Pauwels.
2001. Specific migratory dendritic cells rapidly transport antigen from the
airways to the thoracic lymph nodes. J Exp M e d 193:51.
Lore, K., M . R. Betts, J. M . Brenchley, J. Kuruppu, S. Khojasteh, S. Perfetto,
M . Roederer, R. A. Seder, and R. A. Koup. 2003. Toll-like receptor ligands
modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T
cell responses. J Immunol 171:4320.
Lanzavecchia, A., and F. Sallusto. 2001. Regulation of T cell immunity by
dendritic cells. Cell 106:263.
Zhong, L., A. Granelli-Piperno, Y. Choi, and R. M . Steinman. 1999.
Recombinant adenovirus is an efficient and non-perturbing genetic vector for
human dendritic cells. Eur J Immunol 29:964.
Zhong, L., A. Granelli-Piperno, M . Pope, R. Ignatius, M . G. Lewis, S. S.
Frankel, and R. M . Steinman. 2000. Presentation of SIVgag to monkey T cells
using dendritic cells transfected with a recombinant adenovirus. Eur J
Immunol 30:3281.

140

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

Brown, K., W . Gao, S. Alber, A. Trichel, M . Murphey-Corb, S. C. Watkins,
A. Gambotto, and S. M . Barratt-Boyes. 2003. Adenovirus-transduced
dendritic cells injected into skin or lymph node prime potent simian
immunodeficiency virus-specific T cell immunity in monkeys. J Immunol
171:6875.
Stubbs, A. C , K. S. Martin, C. Coeshott, S. V. Skaates, D. R. Kuritzkes, D.
Bellgrau, A. Franzusoff, R. C. Duke, and C. C. Wilson. 2001. Whole
recombinant yeast vaccine activates dendritic cells and elicits protective cellmediated immunity. Nat M e d 7:625.
Zheng, L., X. L. Huang, Z. Fan, L. Borowski, C. C. Wilson, and C. R.
Rinaldo, Jr. 1999. Delivery of liposome-encapsulated HIV type 1 proteins to
human dendritic cells for stimulation of HIV type 1-specific memory
cytotoxic T lymphocyte responses. A I D S Res H u m Retroviruses 15:1011.
Granelli-Piperno, A., L. Zhong, P. Haslett, J. Jacobson, and R. M . Steinman.
2000. Dendritic cells, infected with vesicular stomatitis virus-pseudotyped
HIV-1, present viral antigens to C D 4 + and C D 8 + T cells from HIV-1-infected
individuals. J Immunol 165:6620.
Chua, B. Y., A. Healy, P. U. Cameron, O. Stock, M . Rizkalla, W . Zeng, J.
Torresi, L. E. Brown, N. L. Fowler, E. J. Gowans, and D. C. Jackson. 2003.
Maturation of dendritic cells with lipopeptides that represent vaccine
candidates for hepatitis C virus. Immunol Cell Biol 81:67.
Condon, C , S. C. Watkins, C. M . Celluzzi, K. Thompson, and L. D. Falo, Jr.
1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat
M e d 2:1122.
Casares, S., K. Inaba, T. D. Brumeanu, R. M . Steinman, and C. A. Bona.
1997. Antigen presentation by dendritic cells after immunization with D N A
encoding a major histocompatibility complex class D-restricted viral epitope.
J Exp M e d 186:1481.
Cusi, M . G., C. Terrosi, G. G. Savellini, G. Di Genova, R. Zurbriggen, and P.
Correale. 2004. Efficient delivery of D N A to dendritic cells mediated by
influenza virosomes. Vaccine 22:735.
Guebre-Xabier, M., S. A. H a m m o n d , D. E. Epperson, J. Yu, L. Ellingsworth,
and G. M . Glenn. 2003. Immunostimulant patch containing heat-labile
enterotoxin from Escherichia coli enhances immune responses to injected
influenza virus vaccine through activation of skin dendritic cells. J Virol
77:5218.
Sailaja, G., S. Husain, B. P. Nayak, and A. M . Jabbar. 2003. Long-term
maintenance of gpl20-specific immune responses by genetic vaccination with
the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand. J Immunol
170:2496.
Bonini, C , S. P. Lee, S. R. Riddell, and P. D. Greenberg. 2001. Targeting
antigen in mature dendritic cells for simultaneous stimulation of C D 4 + and
C D 8 + T cells. J Immunol 166:5250.
Hopkins, S. A., F. Niedergang, I. E. Corthesy-Theulaz, and J. P. Kraehenbuhl.
2000. A recombinant Salmonella typhimurium vaccine strain is taken up and
survives within murine Peyer's patch dendritic cells. Cell Microbiol 2:59.

141

174.

175.

176.

111.

178.

179.

180.
181.
182.
183.
184.

185.
186.
187.

188.
189.

190.

Dietrich, G., A. Kolb-Maurer, S. Spreng, M . Schartl, W . Goebel, and I.
Gentschev. 2001. Gram-positive and Gram-negative bacteria as carrier
systems for D N A vaccines. Vaccine 19:2506.
Xiang, R., F. J. Primus, J. M . Ruehlmann, A. G. Niethammer, S. Silletti, H. N.
Lode, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld. 2001. A dual-function
D N A vaccine encoding carcinoembryonic antigen and C D 4 0 ligand trimer
induces T cell-mediated protective immunity against colon cancer in
carcinoembryonic antigen-transgenic mice. J Immunol 167:4560.
Weth, R., O. Christ, S. Stevanovic, and M . Zoller. 2001. Gene delivery by
attenuated Salmonella typhimurium: comparing the efficacy of helper versus
cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther 8:599.
Gentschev, I., G. Dietrich, S. Spreng, S. Pilgrim, J. Stritzker, A. Kolb-Maurer,
and W . Goebel. 2002. Delivery of protein antigens and D N A by attenuated
intracellular bacteria. Int J M e d Microbiol 291:577.
Reimold, A. M., N. N. Iwakoshi, J. Manis, P. Vallabhajosyula, E.
Szomolanyi-Tsuda, E. M . Gravallese, D. Friend, M . J. Grusby, F. Alt, and L.
H. Glimcher. 2001. Plasma cell differentiation requires the transcription factor
XBP-l. Nature 412:300.
Koito, A., H. Shigekane, and S. Matsushita. 2003. Ability of small animal
cells to support the postintegration phase of human immunodeficiency virus
type-1 replication. Virology 305:181.
Korber, B. 2004. HIV Sequence Database. Los Alamos National Library.
2003. National Center for Biotechnology Information, National Library of
Medicine. National Institutes of Health.
Ulmer, J. B., J. C. Sadoff, and M . A. Liu. 1996. D N A vaccines. Curr Opin
Immunol 8:531.
Robinson, H. L. 1997. Nucleic acid vaccines: an overview. Vaccine 15:785.
Ramsay, A. J., S. J. Kent, R. A. Strugnell, A. Suhrbier, S. A. Thomson, and I.
A. Ramshaw. 1999. Genetic vaccination strategies for enhanced cellular,
humoral and mucosal immunity. Immunol Rev 171:27.
Liu, M . A. 2003. Gene-based Vaccines: Mechanisms, Delivery Systems and
Efficacy. In Keystone Symposia, Breckenridge, C O .
Yewdell, J. W . 2003. Gene-based Vaccines: Mechanisms, Delivery Systems
and Efficacy. In Keyston Symposia, Breckenridge, C O .
Akbari, O., N. Panjwani, S. Garcia, R. Tascon, D. Lowrie, and B. Stockinger.
1999. D N A vaccination: transfection and activation of dendritic cells as key
events for immunity. J Exp M e d 189:169.
Woltman, A. M., and C. van Kooten. 2003. Functional modulation of
dendritic cells to suppress adaptive immune responses. J Leukoc Biol 73:428.
Xiao, B. G., Y. M . Huang, and H. Link. 2003. Dendritic cell vaccine design:
strategies for eliciting peripheral tolerance as therapy of autoimmune diseases.
BioDrugs 17:103.
Bonifaz, L., D. Bonnyay, K. Mahnke, M . Rivera, M . C. Nussenzweig, and R.
M . Steinman. 2002. Efficient targeting of protein antigen to the dendritic cell
receptor DEC-205 in the steady state leads to antigen presentation on major

142

191.

192.

193.
194.
195.

196.

197.
198.

199.

200.

201.

202.

203.

histocompatibility complex class I products and peripheral C D 8 + T cell
tolerance. J Exp M e d 196:1627.
Banchereau, J., A. K. Palucka, M . Dhodapkar, S. Burkeholder, N. Taquet, A.
Rolland, S. Taquet, S. Coquery, K. M . Wittkowski, N. Bhardwaj, L. Pineiro,
R. Steinman, and J. Fay. 2001. Immune and clinical responses in patients with
metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Cancer Res 61:6451.
Palucka, A. K., M . V. Dhodapkar, S. Paczesny, S. Burkeholder, K. M .
Wittkowski, R. M . Steinman, J. Fay, and J. Banchereau. 2003. Single injection
of C D 3 4 + progenitor-derived dendritic cell vaccine can lead to induction of Tcell immunity in patients with stage IV melanoma. JImmunother 26:432.
Ertl, H. 2003. Gene-based Vaccines: Mechanisms, Delivery Systems and
Efficacy. In Keystone Symposia, Breckenridge, C O .
Berzofsky, J. A. 2003. Gene-based Vaccines: Mechanisms, Delivery Systems
and Efficacy. In Keystone Symposia, Breckenridge, C O .
Porgador, A., H. F. Staats, Y. Itoh, and B. L. Kelsall. 1998. Intranasal
immunization with cytotoxic T-lymphocyte epitope peptide and mucosal
adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic
cells in nasal mucosa-associated lymphoid tissue. Infect Immun 66:5876.
Etchart, N., P. O. Desmoulins, K. Chemin, C. Maliszewski, B. Dubois, F.
Wild, and D. Kaiserlian. 2001. Dendritic cells recruitment and in vivo priming
of C D 8 + C T L induced by a single topical or transepithelial immunization via
the buccal mucosa with measles virus nucleoprotein. J Immunol 167:384.
Pope, M . 1999. Mucosal dendritic cells and immunodeficiency viruses. J
Infect Dis 179.S427.
Stumbles, P. A., D. H. Strickland, C. L. Pimm, S. F. Proksch, A. M . Marsh, A.
S. McWilliam, A. Bosco, I. Tobagus, J. A. Thomas, S. Napoli, A. E.
Proudfoot, T. N. Wells, and P. G. Holt. 2001. Regulation of dendritic cell
recruitment into resting and inflamed airway epithelium: use of alternative
chemokine receptors as a function of inducing stimulus. J Immunol 167:228.
Akbari, O., R. H. DeKruyff, and D. T. Umetsu. 2001. Pulmonary dendritic
cells producing IL-10 mediate tolerance induced by respiratory exposure to
antigen. Nat Immunol 2:725.
Jameson, B., F. Baribaud, S. Pohlmann, D. Ghavimi, F. Mortari, R. W . D o m s ,
and A. Iwasaki. 2002. Expression of D C - S I G N by dendritic cells of intestinal
and genital mucosae in humans and rhesus macaques. J Virol 76:1866.
Hu, J., M . B. Gardner, and C. J. Miller. 2000. Simian immunodeficiency virus
rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation
and infects intraepithelial dendritic cells. J Virol 74:6087.
Zhao, X., E. Deak, K. Soderberg, M . Linehan, D. Spezzano, J. Zhu, D. M .
Knipe, and A. Iwasaki. 2003. Vaginal submucosal dendritic cells, but not
Langerhans cells, induce protective Thl responses to herpes simplex virus-2. J
Exp M e d 197:153.
Kelsall, B. L., and W . Strober. 1997. Peyer's patch dendritic cells and the
induction of mucosal immune responses. Res Immunol 148:490.

143

204.
205.

206.

207.

208.

209.
210.

211.

212.

213.

21 A.

215.

Stagg, A. J., M . A. K a m m , and S. C. Knight. 2002. Intestinal dendritic cells
increase T cell expression of alpha4beta7 integrin. Eur J Immunol 32:1445.
Rescigno, M., G. Rotta, B. Valzasina, and P. Ricciardi-Castagnoli. 2001.
Dendritic cells shuttle microbes across gut epithelial monolayers.
Immunobiology 204:572.
Krajina, T., F. Leithauser, P. Moller, Z. Trobonjaca, and J. Reimann. 2003.
Colonic lamina propria dendritic cells in mice with C D 4 + T cell-induced
colitis. Eur J Immunol 33:1073.
Bilsborough, J., T. C. George, A. Norment, and J. L. Viney. 2003. Mucosal
CD8alpha+ D C , with a plasmacytoid phenotype, induce differentiation and
support function of T cells with regulatory properties. Immunology 108:481.
Shreedhar, V. K., B. L. Kelsall, and M . R. Neutra. 2003. Cholera toxin
induces migration of dendritic cells from the subepithelial dome region to Tand B-cell areas of Peyer's patches. Infect Immun 71:504.
Nabel, G. J. 2002. H I V vaccine strategies. Vaccine 20:1945.
Betts, M . R., K. Yusim, and R. A. Koup. 2002. Optimal antigens for H I V
vaccines based on C D 8 + T response, protein length, and sequence variability.
D N A Cell Biol 21:665.
Kaufrnann, D. E., P. M . Bailey, J. Sidney, B. Wagner, P. J. Norris, M . N.
Johnston, L. A. Cosimi, M . M . Addo, M . Lichterfeld, M . Altfeld, N. Frahm,
C. Brander, A. Sette, B. D. Walker, and E. S. Rosenberg. 2004.
Comprehensive Analysis of H u m a n Immunodeficiency Virus Type 1-Specific
C D 4 Responses Reveals Marked Immunodominance of gag and nef and the
Presence of Broadly Recognized Peptides. J Virol 78:4463.
Tang, Y., F. Villinger, S. I. Staprans, R. R. Amara, J. M . Smith, J. G.
Herndon, and H. L. Robinson. 2002. Slowly declining levels of viral R N A and
D N A in DNA/recombinant modified vaccinia virus jAnkara-vaccinated
macaques with controlled simian-human immunodeficiency virus SHIV-89.6P
challenges. J Virol 76:10147.
Tritel, M., A. M . Stoddard, B. J. Flynn, P. A. Darrah, C. Y. W u , U. Wille, J.
A. Shah, Y. Huang, L. Xu, M . R. Betts, G. J. Nabel, and R. A. Seder. 2003.
Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate
guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained
and robust humoral and cellular immune responses. J Immunol 171:2538.
Casimiro, D. R., L. Chen, T. M . Fu, R. K. Evans, M . J. Caulfield, M . E.
Davies, A. Tang, M . Chen, L. Huang, V. Harris, D. C. Freed, K. A. Wilson, S.
Dubey, D. M . Zhu, D. Nawrocki, H. Mach, R. Troutman, L. Isopi, D.
Williams, W . Hurni, Z. Xu, J. G. Smith, S. Wang, X. Liu, L. Guan, R. Long,
W . Trigona, G. J. Heidecker, H. C. Perry, N. Persaud, T. J. Toner, Q. Su, X.
Liang, R. Youil, M . Chastain, A. J. Bett, D. B. Volkin, E. A. Emini, and J. W .
Shiver. 2003. Comparative immunogenicity in rhesus monkeys of D N A
plasmid, recombinant vaccinia virus, and replication-defective adenovirus
vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol
77:6305.
Casimiro, D. R., A. Tang, L. Chen, T. M . Fu, R. K. Evans, M . E. Davies, D.
C. Freed, W . Hurni, J. M . Aste-Amezaga, L. Guan, R. Long, L. Huang, V.

144

216.

217.

218.

219.

220.

221.
222.
223.
224.

225.
226.

227.

Harris, D. K. Nawrocki, H. Mach, R. D. Troutman, L. A. Isopi, K. K. Murthy,
K. Rice, K. A. Wilson, D. B. Volkin, E. A. Emini, and J. W . Shiver. 2003.
Vaccine-induced immunity in baboons by using D N A and replicationincompetent adenovirus type 5 vectors expressing a human immunodeficiency
virus type 1 gag gene. J Virol 77:7663.
Otten, G., M . Schaefer, C. Greer, M . Calderon-Cacia, D. Coit, J. Kazzaz, A.
Medina-Selby, M . Selby, M . Singh, M . Ugozzoli, J. zur Megede, S. W .
Barnett, D. O'Hagan, J. Donnelly, and J. Ulmer. 2003. Induction of broad and
potent anti-human immunodeficiency virus immune responses in rhesus
macaques by priming with a D N A vaccine and boosting with protein-adsorbed
polylactide coglycolide microparticles. J Virol 77:6087.
Patterson, L. J., N. Malkevitch, D. Venzon, J. Pinczewski, V. R. GomezRoman, L. Wang, V. S. Kalyanaraman, P. D. Markham, F. A. Robey, and M .
Robert-Guroff. 2004. Protection against mucosal simian immunodeficiency
virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene
vaccine priming and subunit boosting. J Virol 78:2212.
Leung, L., I. K. Srivastava, E. Kan, H. Legg, Y. Sun, C. Greer, D. C.
Montefiori, J. Z. Megede, and S. W . Barnett. 2004. Immunogenicity of HIV-1
Env and Gag in baboons using a D N A prime/protein boost regimen. Aids
18:991.
M w a u , M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, E. G. W e e , T.
Beattie, Y. H. Chen, L. Dorrell, H. McShane, C. Schmidt, M . Brooks, S. Patel,
J. Roberts, C. Conlon, S. L. Rowland-Jones, J. J. Bwayo, A. J. McMichael,
and T. Hanke. 2004. A human immunodeficiency virus 1 (HIV-1) clade A
vaccine in clinical trials: stimulation of HIV-specific T-cell responses by
D N A and recombinant modified vaccinia virus Ankara ( M V A ) vaccines in
humans .J Gen Virol 85:911.
Shiver, J. W., and E. A. Emini. 2004. Recent advances in the development of
HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev
M e d 55:355.
Barouch, D. H., and N. L. Letvin. 2001. C D 8 + cytotoxic T lymphocyte
responses to lentiviruses and herpesviruses. Curr Opin Immunol 13:479.
Serbina, N., and E. G. Pamer. 2003. Quantitative studies of C D 8 + T-cell
responses during microbial infection. Curr Opin Immunol 15:436.
Gregoriades, A., G. G. Guzman, and E. Paoletti. 1990. The phosphorylation of
the integral membrane (Ml) protein of influenza virus. Virus Res 16:27.
Herlocher, M . L., D. Bucher, and R. G. Webster. 1992. Host range
determination and functional mapping of the nucleoprotein and matrix genes
of influenza viruses using monoclonal antibodies. Virus Res 22:281.
Tada, Y., S. Hongo, Y. Muraki, K. Sugawara, F. Kitame, and K. Nakamura.
1997. Evolutionary analysis of influenza C virus M genes. Virus Genes 15:53.
Reid, A. H., T. G. Fanning, T. A. Janczewski, S. McCall, and J. K.
Taubenberger. 2002. Characterization of the 1918 "Spanish" influenza virus
matrix gene segment. J Virol 76:10717.
Hui, E. K., K. Ralston, A. K. Judd, and D. P. Nayak. 2003. Conserved
cysteine and histidine residues in the putative zincfingermotif of the

145

228.

229.

230.

231.

232.

233.

234.

235.

236.
237.
238.

239.

240.

influenza A virus M l protein are not critical for influenza virus replication. J
Gen Virol 84:3105.
Okuda, K., A. Diata, S. Watabe, E. Okada, T. Yamakawa, K. Hamajima, J.
Yang, N. Ishii, M . Nakazawa, K. Ohnari, K. Nakajima, and K. Q. Xin. 2001.
Protective immunity against influenza A virus induced by immunization with
D N A plasmid containing influenza M gene. Vaccine 19:3681.
Plotnicky, H., D. Cyblat-Chanal, J. P. Aubry, F. Derouet, C. KlinguerHamour, A. Beck, J. Y. Bonnefoy, and N. Corvaia. 2003. The
immunodominant influenza matrix T cell epitope recognized in human
induces influenza protection in HLA-A2/K(b) transgenic mice. Virology
309:320.
Dhodapkar, M . V., R. M . Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj.
2001. Antigen-specific inhibition of effector T cell function in humans after
injection of immature dendritic cells. J Exp M e d 193:233.
Larsson, M., J. F. Fonteneau, S. Somersan, C. Sanders, K. Bickham, E. K.
Thomas, K. Mahnke, and N. Bhardwaj. 2001. Efficiency of cross presentation
of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol
31:3432.
Ponsaerts, P., G. Van den Bosch, N. Cools, A. Van Driessche, G. Nijs, M .
Lenjou, F. Lardon, C. Van Broeckhoven, D. R. Van Bockstaele, Z. N.
Berneman, and V. F. Van Tendeloo. 2002. Messenger R N A electroporation of
human monocytes, followed by rapid in vitro differentiation, leads to highly
stimulatory antigen-loaded mature dendritic cells. J Immunol 169:1669.
Hu, P. Q., R. J. Tuma-Warrino, M . A. Bryan, K. G. Mitchell, D. E. Higgins, S.
C. Watkins, and R. D. Salter. 2004. Escherichia coli expressing recombinant
antigen and listeriolysin O stimulate class I-restricted C D 8 + T cells following
uptake by human .APC. J Immunol 172:1595.
Migueles, S. A., A. C. Laborico, W . L. Shupert, M . S. Sabbaghian, R. Rabin,
C. W . Hallahan, D. Van Baarle, S. Kostense, F. Miedema, M . McLaughlin, L.
Ehler, J. Metcalf, S. Liu, and M . Connors. 2002. HIV-specific C D 8 + T cell
proliferation is coupled to perforin expression and is maintained in
nonprogressors. Nat Immunol 3:1061.
Arrode, G., J. S. Finke, H. Zebroski, F. P. Siegal, and R. M . Steinman. 2004.
C D 8 + T cells from most HIV-1 infected patients, even when challenged with
mature dendritic cells, lack functional recall memory to HIV gag but not other
viruses. J Clin Invest (submitted).
Dhodapkar, K. 2003. unpublished data.
Arrode, G. 2004. unpublished data.
Bao, J. X., and J. D. Clements. 1991. Prior immunologic experience
potentiates the subsequent antibody response when Salmonella strains are
used as vaccine carriers. Infect Immun 59:3841.
Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M . Kaech, R.
Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and
protective immunity of memory C D 8 T cell subsets. Nat Immunol 4:225.
Johnson, B. J., E. O. Costelloe, D. R. Fitzpatrick, J. B. Haanen, T. N.
Schumacher, L. E. Brown, and A. Kelso. 2003. Single-cell perforin and

146

241.

242.

243.

244.

245.

246.

247.

248.

249.

250.

granzyme expression reveals the anatomical localization of effector C D 8 + T
cells in influenza virus-infected mice. Proc Natl Acad Sci U S A 100:2657.
Ewen, C , K. P. Kane, I. Shostak, P. J. Griebel, E. M . Bertram, T. H. Watts, R.
C. Bleackley, and J. E. McElhaney. 2003. A novel cytotoxicity assay to
evaluate antigen-specific C T L responses using a colorimetric substrate for
Granzyme B. J Immunol Methods 276:89.
Lichterfeld, M., X. G. Yu, M . T. Waring, S. K. Mui, M . Johnston, D. Cohen,
M . M . Addo, J. Zaunders, G. Alter, E. Pae, D. Stride, T. M . Allen, E. S.
Rosenberg, B. D. Walker, and M . Altfeld. 2004. HIV-1-specific cytotoxicity
is preferentially mediated by a subset of C D 8 + T cells producing both
interferon-{gamma} and tumor-necrosis factor-{alpha}. Blood 1:1.
Betts, M . R., J. M . Brenchley, D. A. Price, S. C. D e Rosa, D. C. Douek, M .
Roederer, and R. A. Koup. 2003. Sensitive and viable identification of
antigen-specific C D 8 + T cells by a flow cytometric assay for degranulation. J
Immunol Methods 281:65.
He, X. S., B. Rehermann, J. Boisvert, J. M u m m , H. T. Maecker, M . Roederer,
T. L. Wright, V. C. Maino, M . M . Davis, and H. B. Greenberg. 2001. Direct
functional analysis of epitope-specific C D 8 + T cells in peripheral blood. Viral
Immunol 14:59.
D e Rosa, S. C , F. X. Lu, S. P. Perfetto, S. Moser, C. J. Miller, T. G. Evans,
and M . Roederer. 2003. Vaccination in Humans Generates Broad T-Cell
Cytokine Responses. In A I D S Vaccine 2003, N e w York.
D e Rosa, S. C , S. Perfetto, R. Bailer, L. Lamoreaux, R. A. Koup, and M .
Roederer. 2004. Cytokine Profiles of T-cell Responses Induced by Vaccines
and Natural Infection. In 11th Conference on Retroviruses and Opportunistic
Infections, San Francisco.
Lifson, J. D., J. L. Rossio, M . Piatak, Jr., T. Parks, L. Li, R. Kiser, V. Coalter,
B. Fisher, B. M . Flynn, S. Czajak, V. M . Hirsch, K. A. Reimann, J. E.
Schmitz, J. Ghrayeb, N. Bischofberger, M . A. Nowak, R. C. Desrosiers, and
D. Wodarz. 2001. Role of CD8(+) lymphocytes in control of simian
immunodeficiency virus infection and resistance to rechallenge after transient
early antiretroviral treatment. J Virol 75:10187.
Lifson, J. D., M . Piatak, Jr., A. N. Cline, J. L. Rossio, J. Purcell, I. Pandrea, N.
Bischofberger, J. Blanchard, and R. S. Veazey. 2003. Transient early postinoculation anti-retroviral treatment facilitates controlled infection with
sparing of C D 4 + T cells in gut-associated lymphoid tissues in SIVmac239infected rhesus macaques, but not resistance to rechallenge. J M e d Prima to I
32:201.
Altfeld, M., T. M . Allen, X. G. Yu, M . N. Johnston, D. Agrawal, B. T.
Korber, D. C. Montefiori, D. H. O'Connor, B. T. Davis, P. K. Lee, E. L.
Maier, J. Harlow, P. J. Goulder, C. Brander, E. S. Rosenberg, and B. D.
Walker. 2002. HIV-1 superinfection despite broad C D 8 + T-cell responses
containing replication of the primary virus. Nature 420:434.
Ludewig, B., S. Ehl, U. Karrer, B. Odermatt, H. Hengartner, and R. M .
Zinkernagel. 1998. Dendritic cells efficiently induce protective antiviral
immunity. J Virol 72:3812.

147

251.

252.
253.
254.
255.
256.
257.
258.

259.
260.

261.

262.

263.

264.

265.

266.

267.

Avery, O. T., C. M . MacLeod, and M . McCarty. 1944. Studies on the
chemical nature of the substance inducing transformation of pneumococcal
types. Inductions of transformation by a desoxyribonucleic acid fraction
isolated from pneumococcus type DI. J Exp M e d 79:137.
Ochman, H., J. G. Lawrence, and E. A. Groisman. 2000. Lateral gene transfer
and the nature of bacterial innovation. Nature 405:299.
Gogarten, J. P., L. Olendzenski, E. Hilario, C. Simon, and K. E. Holsinger.
1996. Dating the cenancester of organisms. Science 274:1750.
Martin, W., and M . Muller. 1998. The hydrogen hypothesis for the first
eukaryote. Nature 392:37.
Doolittle, W . F. 1998. A paradigm gets shifty. Nature 392:15.
Doolittle, W . F. 1999. Phylogenetic classification and the universal tree.
Science 284:2124.
Kurland, C. G., B. Canback, and O. G. Berg. 2003. Horizontal gene transfer: a
critical view. Proc Natl Acad Sci U S A 100:9658.
Escudero, J., G. Neuhaus, and B. Hohn. 1995. Intracellular Agrobacterium can
transfer D N A to the cell nucleus of the host plant. Proc Natl Acad Sci U S A
92:230.
Schaffner, W . 1980. Direct transfer of cloned genes from bacteria to
mammalian cells. Proc Natl Acad Sci U S A 77:2163.
Ishibashi, Y., and T. AraL 1990. Roles of the complement receptor type 1
(CR1) and type 3 (CR3) on phagocytosis and subsequent phagosomelysosome fusion in Salmonella-infected murine macrophages. F E M S
Microbiol Immunol 2:89.
Ishibashi, Y., and T. Arai. 1990. Specific inhibition of phagosome-lysosome
fusion in murine macrophages mediated by Salmonella typhimurium
infection. F E M S Microbiol Immunol 2:35.
Buchmeier, N. A., and F. Heffron. 1991. Inhibition of macrophage
phagosome-lysosome fusion by Salmonella typhimurium. Infect Immun
59:2232.
Rathman, M., L. P. Barker, and S. Falkow. 1997. The unique trafficking
pattern of Salmonella typhimurium-containing phagosomes in murine
macrophages is independent of the mechanism of bacterial entry. Infect
Immun 65:1475.
Meresse, S., O. Steele-Mortimer, E. Moreno, M . Desjardins, B. Finlay, and J.
P. Gorvel. 1999. Controlling the maturation of pathogen-containing vacuoles:
a matter of life and death. Nat Cell Biol 1:E183.
Baldeon, M . E., B. P. Ceresa, and J. E. Casanova. 2001. Expression of
constitutively active Rab5 uncouples maturation of the Salmonella-containing
vacuole from intracellular replication. Cell Microbiol 3:473.
Uchiya, K., M . A. Barbieri, K. Funato, A. H. Shah, P. D. Stahl, and E. A.
Groisman. 1999. A Salmonella virulence protein that inhibits cellular
trafficking. E m b o J 18:3924.
Steele-Mortimer, O., S. Meresse, J. P. Gorvel, B. H. Toh, and B. B. Finlay.
1999. Biogenesis of Salmonella typhimurium-containing vacuoles in epithelial

148

cells involves interactions with the early endocytic pathway. Cell Microbiol
1:33.
268.

269.

270.

271.
272.

273.

21 A.

275.
276.
211.
278.

279.

280.
281.

282.

Brumell, J. H., C. M . Rosenberger, G. T. Gotto, S. L. Marcus, and B. B.
Finlay. 2001. SifA permits survival and replication of Salmonella
typhimurium in murine macrophages. Cell Microbiol 3:75.
Brumell, J. H., P. Tang, S. D. Mills, and B. B. Finlay. 2001. Characterization
of Salmonella-inducedfilaments(Sifs) reveals a delayed interaction between
Salmonella-containing vacuoles and late endocytic compartments. Traffic
2:643.
Vazquez-Torres, A., Y. Xu, J. Jones-Carson, D. W . Holden, S. M . Lucia, M .
C. Dinauer, P. Mastroeni, and F. C. Fang. 2000. Salmonella pathogenicity
island 2-dependent evasion of the phagocyte N A D P H oxidase. Science
287:1655.
Vazquez-Torres, A., and F. C. Fang. 2001. Salmonella evasion of the N A D P H
phagocyte oxidase. Microbes Infect 3:1313.
Gallois, A., J. R. Klein, L. A. Allen, B. D. Jones, and W . M . Nauseef 2001.
Salmonella pathogenicity island 2-encoded type ID secretion system mediates
exclusion of N A D P H oxidase assembly from the phagosomal membrane. J
Immunol 166:5741.
Kubori, T., and J. E. Galan. 2003. Temporal regulation of salmonella
virulence effector function by proteasome-dependent protein degradation. Cell
115:333.
Garcia-Del Portillo, F., H. Jungnitz, M . Rohde, and C. A. Guzman. 2000.
Interaction of Salmonella enterica serotype Typhimurium with dendritic cells
is defined by targeting to compartments lacking lysosomal membrane
glycoproteins. Infect Immun 68:2985.
Roy, C. R. 2003. Immunology: professional secrets. Nature 425:351.
Shedlock, D. J., and D. B. Weiner. 2000. D N A vaccination: antigen
presentation and the induction of immunity. J Leukoc Biol 68:793.
Barry, M . A., and S. A. Johnston. 1997. Biological features of genetic
immunization. Vaccine 15:788.
Fynan, E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H.
L. Robinson. 1993. D N A vaccines: protective immunizations by parenteral,
mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 90:11478.
McKeever, U., S. Barman, T. Hao, P. Chambers, S. Song, L. Lunsford, Y. Y.
Hsu, K. Roy, and M . L. Hedley. 2002. Protective immune responses elicited
in mice by immunization with formulations of poly(lactide-co-glycolide)
microparticles. Vaccine 20:1524.
O'Hagan, D. T., and M . Singh. 2003. Microparticles as vaccine adjuvants and
delivery systems. Expert Rev Vaccines 2:269.
Dietrich, G., I. Gentschev, J. Hess, J. B. Ulmer, S. H. Kaufrnann, and W .
Goebel. 1999. Delivery of D N A vaccines by attenuated intracellular bacteria.
Immunol Today 20:251.
Hormaeche, C. E., H. S. Joysey, L. Desilva, M . Izhar, and B. A. Stocker.
1990. Immunity induced by live attenuated Salmonella vaccines. Res
Microbiol 141:757.

149

283.

284.

285.
286.
287.
288.

289.
290.

Hormaeche, C. E., P. Mastroeni, J. A. Harrison, R. Demarco de Hormaeche,
S. Svenson, and B. A. Stocker. 1996. Protection against oral challenge three
months after i.v. immunization of BALB/c mice with live Aro Salmonella
typhimurium and Salmonella enteritidis vaccines is serotype (species)dependent and only partially determined by the main LPS O antigen. Vaccine
14:251.
Belyakov, I. M., B. Moss, W . Strober, and J. A. Berzofsky. 1999. Mucosal
vaccination overcomes the barrier to recombinant vaccinia immunization
caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A 96:4512.
Donnelly, J. J., J. B. Ulmer, J. W . Shiver, and M . A. Liu. 1997. D N A
vaccines. Annu Rev Immunol 15:617.
Courvalin, P., S. Goussard, and C. Grillot-Courvalin. 1995. Gene transfer
from bacteria to mammalian cells. C R Acad Sci III 318:1207.
Medina, E., and C. A. Guzman. 2001. Use of live bacterial vaccine vectors for
antigen delivery: potential and limitations. Vaccine 19:1573.
Grillot-Courvalin, C , S. Goussard, F. Huetz, D. M . Ojcius, and P. Courvalin.
1998. Functional gene transfer from intracellular bacteria to mammalian cells.
Nat Biotechnol 16:862.
Pawelek, J. M., K. B. Low, and D. Bermudes. 1997. Tumor-targeted
Salmonella as a novel anticancer vector. Cancer Res 57:4537.
Low, K. B., M . Ittensohn, T. Le, J. Piatt, S. Sodi, M . Amoss, O. Ash, E.
Carmichael, A. Chakraborty, J. Fischer, S. L. Lin, X. Luo, S. I. Miller, L.
Zheng, I. King, J. M . Pawelek, and D. Bermudes. 1999. Lipid A mutant
Salmonella with suppressed virulence and TNFalpha induction retain tumortargeting in vivo. Nat Biotechnol 17:37.

150

